Synchronous bilateral breast cancer at the time of diagnosisXx_NEWLINE_xXIpsilateral breast had a previous cancer and/or prior in-field radiationXx_NEWLINE_xXUnilateral DCIS: contralateral normal mammogram ? 6 months of registration and ipsilateral breast imaging ? 90 days of registration (must include ipsilateral mammogram; can also include ultrasound or breast MRI)Xx_NEWLINE_xXBilateral DCIS: bilateral breast imaging ? 90 days of registration (must include bilateral mammogram; can also include ultrasound or breast MRI)Xx_NEWLINE_xXConcurrent diagnosis of invasive or microinvasive breast cancer in either breastXx_NEWLINE_xXPatients must not have metastatic breast cancer (stage IV disease); patients with multifocal, multicentric, and synchronous bilateral, and primary inflammatory breast cancers are allowed\r\n* Multifocal disease is defined as more than one invasive cancer < 2 cm from the largest lesion within the same breast quadrant\r\n* Multicentric disease is defined as more than one invasive cancer >= 2 cm from the largest lesion within the same breast quadrant or more than one lesion in different quadrants\r\n* Synchronous bilateral disease is defined as invasive breast cancer with positive lymph nodes (axillary or intramammary) in at least one breast, diagnosed within 30 days of each other; (NOTE: the tumor with the highest recurrence score should be used)Xx_NEWLINE_xXThe interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 60 daysXx_NEWLINE_xXT4 tumors including inflammatory breast cancerXx_NEWLINE_xXChemotherapy administered for the currently diagnosed breast cancer prior to randomizationXx_NEWLINE_xXNo inflammatory breast cancerXx_NEWLINE_xXClinical T2-T4c, any N, M0 invasive breast cancer, by American Joint Committee on Cancer (AJCC) 7th edition clinical staging, with the goal being surgery to complete excision of the tumor in the breast and the lymph node\r\nPrimary tumor must be:\r\n* Palpable\r\n* Its largest tumor diameter is > 2.0 cm by physical examination or by radiological assessment\r\n* Bi-dimensional measurement by tape, ruler or caliper technique must be provided\r\n** Note:\r\n*** Patients with contralateral ductal carcinoma in situ and/or invasive breast cancer are not eligible\r\n*** Patients with multi-focal breast cancer (defined as more than one lesion of invasive breast cancer in the same breast separated from the dominant breast lesion by less than 5 cm of radiologically normal breast tissue) are eligible; if the other lesions have been biopsied (biopsy not required) they must meet the estrogen receptor/human epidermal growth factor receptor 2 (ER/HER2) eligibility requirements; research biopsies and Ki67 assessment and radiological measures are to be performed on the dominant breast lesionXx_NEWLINE_xXInflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d’orange without erythema)Xx_NEWLINE_xXAn excisional biopsy of this breast cancerXx_NEWLINE_xXBreast implants are contraindicated only if the implant precludes the required research biopsies or interferes with palpating the breast lesionXx_NEWLINE_xXT4 tumors including inflammatory breast cancerXx_NEWLINE_xXAny radiation therapy for the currently diagnosed breast cancer prior to randomizationXx_NEWLINE_xXPathologically confirmed metastatic breast cancerXx_NEWLINE_xXT4 tumors including inflammatory breast cancerXx_NEWLINE_xXAny radiation therapy (RT) for the currently diagnosed breast cancer prior to study enrollmentXx_NEWLINE_xXHistory of ipsilateral or contralateral breast or thoracic RT for any conditionXx_NEWLINE_xXSynchronous contralateral breast cancer requiring RTXx_NEWLINE_xXOverall geometry (eg, breast size if intact breast) precludes the ability to achieve dosimetric requirements \r\n* Note: Set-up devices for breast positioning are permittedXx_NEWLINE_xXBRCA 1/2- associated metastatic breast carcinomaXx_NEWLINE_xXGroup 3: Triple negatice breast cancer.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed breast cancer, with diagnosed or suspected metastatic, inoperable locally advanced breast cancer, or inoperable locally recurrent breast cancer for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXPatients who have had any prior chemotherapy, or endocrine therapy for the treatment of breast cancer or any other cancerXx_NEWLINE_xXPatients with breast cancer and gastric and gastroesophageal junction cancer must have received at least 1 prior HER2 targeted therapy for advanced/metastatic disease.Xx_NEWLINE_xXER+ breast cancer patients harboring the AKT1 E17K mutation (patient population tested in MSK IRB# 14-214, study D3610C00001 part E, ClinicalTrials.gov NCT01226316)Xx_NEWLINE_xXNo prior systemic treatment for metastatic breast cancerXx_NEWLINE_xXPathologic confirmation of metastatic breast cancer diagnosed by core needle biopsyXx_NEWLINE_xXCohort A Dose Escalation (Ribociclib + PDR001): Breast participants:\r\n* Hormone receptor (HR)-positive, HER2-negative metastatic breast cancer according to American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines\r\n* Men are eligible, as long as on a gonadotropin releasing hormone (GNRH) agonist for at least 6 weeks prior to study entry; men MUST remain on the GnRH agonist for the duration of protocol\r\n* Prior Chemotherapy: Participants may have received any number of prior lines of chemotherapy for advanced breast cancer, as long as the last dose is >= 21 days prior to first dose of study treatment.Xx_NEWLINE_xXExpanded Cohort: must have breast cancer.Xx_NEWLINE_xXRecurrent ipsilateral breast cancerXx_NEWLINE_xXOpen surgery in ipsilateral breast within 1 year.Xx_NEWLINE_xXPrior malignancy, other than breast cancer, active within the last 6 monthsXx_NEWLINE_xXTriple negative breast cancer.Xx_NEWLINE_xXTriple negative breast cancer (TNBC)Xx_NEWLINE_xXTriple Negative Breast Cancer (TNBC) (DXx_NEWLINE_xXFor Part A dose confirmation: All participants must have histological evidence of advanced or metastatic soft tissue sarcoma or breast cancer. Breast cancer participants must have prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway.Xx_NEWLINE_xXLocally recurrent breast cancerXx_NEWLINE_xXPatients must have the clinical diagnosis of inflammatory breast cancer as evidenced by the onset of signs and symptoms noted below within a 6 month time-period:\r\n* Erythema of the breast\r\n* Edema of the skin of the breast\r\n* Enlargement of the breastXx_NEWLINE_xXPatients may have bilateral breast cancer so long as one breast meets criteria for inflammatory breast cancer, and neither breast cancer has received prior therapyXx_NEWLINE_xXMetastatic breast cancer that is measurable (Stage 1) or early breast cancer with a primary tumor size greater than (>) 2 centimeter (cm) (Stage 2)Xx_NEWLINE_xXPatients with inflammatory breast cancer are eligible if they meet both of the following criteria:\r\n* Patient has an underlying, clinically palpable breast mass of at least 2 cm, AND\r\n* A corresponding lesion is visualized on mammogram or ultrasoundXx_NEWLINE_xXAny prior systemic therapy for breast cancer within 5 yearsXx_NEWLINE_xXMetastatic breast cancer (measurable or evaluable including bone metastases only)Xx_NEWLINE_xXAny number of prior therapies for metastatic breast cancer is allowed; patients with weakly estrogen receptor positive breast cancer who received any number of endocrine agents for metastatic breast cancer will also be eligibleXx_NEWLINE_xXPrior or concurrent use of hormonal therapy, chemotherapy, radiation therapy, or novel therapy to treat the current breast cancer, including any history of prior irradiation to the ipsilateral breast; additionally, the patient must not have had hormonal therapy for breast cancer treatment or for breast cancer prevention within 2 years prior to study enrollment; Note: Synchronous breast, cancer (including bilateral breast cancer) at separate sites is permissible, provided the patient does not receive medical treatments for breast cancer or radiation therapy to the ipsilateral breast during the 21 day study intervention periodXx_NEWLINE_xXUnifocal primary disease NOTE: Patients with multifocal and/or multicentric in breast cancer, or evidence of EIC are NOT eligible. Patients with contralateral disease will remain eligible.Xx_NEWLINE_xXBreast size adequate for safe cryoablationXx_NEWLINE_xXPresence of microinvasion, or invasive breast carcinoma with extensive intraductal component (EIC) 4. Presence of multifocal and/or multicentric in breast cancer 5. Presence of multifocal calcifications 6. Presence of prior or concurrent neoadjuvant chemotherapy for breast cancerXx_NEWLINE_xXPatients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer; patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsyXx_NEWLINE_xXHave metastatic breast cancer with severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of the disease.Xx_NEWLINE_xXMetastatic non-gynecologic or breast primariesXx_NEWLINE_xXBreast cancer patientsXx_NEWLINE_xXNo prior chemotherapy or trastuzumab for treatment of metastatic breast cancerXx_NEWLINE_xXHave a diagnosis of metastatic triple negative breast cancer (TNBC) • Up to 1-2 prior lines of chemotherapyXx_NEWLINE_xXAt least one line of prior systemic therapy for metastatic or recurrent breast cancer (there is no limit to the number of prior therapies)Xx_NEWLINE_xXFNA alone to diagnose the breast cancer.Xx_NEWLINE_xXPhase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors).Xx_NEWLINE_xXCohort 1: advanced breast cancer, ISH positive or IHC 3+.Xx_NEWLINE_xXCohort 2: advanced breast cancer, ISH negative with IHC 2+.Xx_NEWLINE_xXParticipant with inflammatory breast cancer.Xx_NEWLINE_xXStage 4 (metastatic) breast cancerXx_NEWLINE_xXPrior systemic therapy for treatment and prevention of breast cancerXx_NEWLINE_xXBilateral breast cancerXx_NEWLINE_xXCancer patients with stage 0-III breast cancer (BrCA) treated with breast conserving surgery or mastectomy and clear margins will be recruited to the studyXx_NEWLINE_xXPatients must have one or more of the following characteristics and be eligible for breast or chest wall with or without regional nodal radiotherapy:\r\n* Prior chemotherapy for breast cancer\r\n* > 25 cm of breast separation (the largest distance on an axial slice of the planning computed tomography [CT] simulation scan between the entry and exit points of the radiation beam on the body)\r\n* Non-Caucasian race\r\n* Requiring regional nodal irradiation without evidence of N3 diseaseXx_NEWLINE_xXAny breast cancer patient with metastatic or locally recurrent unresectable breast cancer currently progressive, after at least two prior lines of therapy in the advanced setting; patients with HER2+ disease must have failed two or more different anti-HER2 agentsXx_NEWLINE_xXFor patients who have undergone lumpectomy, there are no breast size limitationsXx_NEWLINE_xXBilateral breast cancer is permitted; patients with bilateral breast cancer will be stratified as left-sidedXx_NEWLINE_xXAny radiation therapy for the currently diagnosed breast cancer prior to randomizationXx_NEWLINE_xXPatients with stage II-III breast cancer are eligible if they are deemed appropriate for neoadjuvant endocrine therapy by the referring or treating medical oncologist. Patients with stage I disease are eligible if they are deemed borderline candidates for breast conservation and the treating surgeon recommends preoperative therapy to increase the chances of breast conservation.Xx_NEWLINE_xXPatient must be willing to undergo breast biopsies as required by the study protocol.Xx_NEWLINE_xXadvanced triple negative breast cancer,Xx_NEWLINE_xXRadiotherapy must begin within 12 weeks of last surgery (breast or axilla) or last chemotherapy\r\n* Note: Breast implants and expanders allowedXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXRecurrent breast cancerXx_NEWLINE_xXPatient has elected breast-conserving surgery (BCS) as surgical treatment for early-stage breast cancerXx_NEWLINE_xXPatients must meet one of the following criteria:\r\n* Pre-pathology cohort: Patient has new diagnosis of breast cancer and has elected BCS; these patients must be consented prior to the scheduled BCS with precision breast IORT; BCS (either primary breast surgery or re-excision) will occur one same date as precision breast IORT\r\n* Post-pathology cohort: Patient was previously treated for breast cancer with BCS; precision breast IORT will occur as a separate procedure within 30 days of breast surgery; these patients should be consented after they have completed the initial excision and histological confirmation of eligibilityXx_NEWLINE_xXBreast cancer that involves the skin or chest wallXx_NEWLINE_xXHistory of ipsilateral breast cancer treated with radiation therapyXx_NEWLINE_xXMulticentric breast cancer in the ipsiltateral breast as diagnosed by clinical exam, mammogram, ultrasound or magnetic resonance imaging (MRI)Xx_NEWLINE_xXFor patients in the post-pathology stratification, precision breast IORT must be delivered within 30 days of the last breast cancer surgery (not axillary)Xx_NEWLINE_xXMust have a life expectancy of at least 10 years based on age and comorbidities but excluding diagnosis of breast cancer.Xx_NEWLINE_xXNote: Multicentric breast cancer and Paget's disease of the nipple are permitted.Xx_NEWLINE_xXPrior history of breast cancer.Xx_NEWLINE_xXPART I: Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancerXx_NEWLINE_xXPART II: Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer are allowedXx_NEWLINE_xXPatients who received tamoxifen or another selective estrogen receptor modulator (SERM) for prevention or treatment of breast cancer or for other indications (e.g., osteoporosis, prior ductal carcinoma in situ [DCIS]), or who receive aromatase inhibitors for prevention or treatment of breast cancer, are eligible; patients who are hormone-receptor positive and who have received other hormonal agents for the treatment of breast cancer (e.g., Fulvestrant) are also eligible; tamoxifen therapy or other hormonal agents should be discontinued at least 1 week before the patient is enrolled on this studyXx_NEWLINE_xXPart B7: Must have a diagnosis of HR+ and HER2- breast cancer; have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease; no previous treatment or currently receiving 1 of the following treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy, endocrine therapy, CDK4/6 inhibitor, and PI3K and/or mTOR inhibitor)Xx_NEWLINE_xXNormal mammogram of unaffected breast within 12 months prior to study entryXx_NEWLINE_xXBreast cancer:\r\n* Patients inappropriate for standard breast conservation therapy (multicentric disease, inability to achieve clear margins)\r\n* Male patients with breast cancer\r\n* Autoimmune disorders, including systemic lupus erythematosus (SLE), scleroderma, etc\r\n* Distant metastasesXx_NEWLINE_xXPrior therapies for metastatic breast cancer\r\n* Frontline patients who have not received prior systemic therapy for metastatic breast cancer are eligible, \r\n* Patients who have received =< 2 prior chemotherapy regimens for metastatic breast cancer are eligibleXx_NEWLINE_xXDiagnosis of inflammatory breast cancerXx_NEWLINE_xXClinical stage I or II breast cancer for which there will be at least a 2 week period of time between diagnosis and definitive surgeryXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients must have at least one lesion deemed safe to biopsy and be willing to undergo mandatory biopsiesXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have undergone radiotherapy within 4 weeks of first dose of study treatmentXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must have received at least one line of prior chemotherapy in the metastatic settingXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must have at least one lesion deemed safe to biopsy and be willing to undergo mandatory biopsiesXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients who have undergone radiotherapy within 4 weeks of first dose of study treatmentXx_NEWLINE_xXClinical stage I-III breast cancer with any invasive residual disease in the breast or axillary nodes following neoadjuvant chemotherapy including HER-2 directed treatmentXx_NEWLINE_xXWomen with metastatic breast cancer who are eligible for capecitabine monotherapy; for HER2 positive breast cancer, concurrent trastuzumab is allowed ORXx_NEWLINE_xXPresence of a clip in the primary breast cancerXx_NEWLINE_xXPlanned for multidisciplinary evaluation by a breast surgical oncologist and breast radiation oncologist. For patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeonXx_NEWLINE_xXPrior fulvestrant for metastatic breast cancer will be allowed for phase 1 portion but not for the phase 2 portionXx_NEWLINE_xXNo prior radiation to the ipsilateral breast, a history of contralateral breast radiation is permittedXx_NEWLINE_xXMulticentric breast cancer, defined as discontiguous tumors separated by at least 5 cm of uninvolved tissue or discontiguous tumors that are located within separate breast quadrants either clinical or mammographicallyXx_NEWLINE_xXHistory of ipsilateral cosmetic or reconstructive breast surgeryXx_NEWLINE_xXHas been a participant in Study WRI-GEV-007, \A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients\Xx_NEWLINE_xXHave histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site which has failed prior therapy.Xx_NEWLINE_xXTriple Negative tumors: Must have exhausted other available therapies including prior treatment with a taxane and carboplatin. Patients with new or progressive breast cancer metastatic to brain will be eligible provided:Xx_NEWLINE_xXMale breast cancer patients. 19. Patients may not be on a concurrent clinical trial, unless approved by Investigator.Xx_NEWLINE_xXWomen with non-metastatic breast cancer with any hormone receptor and Her 2 neu status who have completed surgery, chemotherapy, and radiation and are currently on endocrine therapy, single agent Herceptin, or observationXx_NEWLINE_xXPatients with metastatic breast cancerXx_NEWLINE_xXHistological diagnosis of breast cancerXx_NEWLINE_xXPlanning to remain on current breast cancer therapy for at least 12 weeksXx_NEWLINE_xXAt least one prior line of therapy for metastatic breast cancerXx_NEWLINE_xXPatients must have had at least one prior line of therapy for breast cancer in the metastatic settingXx_NEWLINE_xXPatients must have an accessible lesion in the breast/chest wall/axilla which has not been previously thermally ablated; prior breast irradiation is acceptable if the lesion has recurred or grown following radiationXx_NEWLINE_xXCOHORT 1 (TRIPLE-NEGATIVE BREAST CANCER [TNBC])Xx_NEWLINE_xXPatients with ER+ breast cancer must have progressed on at least 2 lines of endocrine therapyXx_NEWLINE_xXPTEN or PIK3CB mutated advanced solid tumor\r\n* PTEN loss of function mutation or PIK3CB gain of function mutation identified by local Clinical Laboratory Improvement Act (CLIA) certified next generation sequencing (NGS)\r\n* Breast cancers patients enrolled on this study must have either:\r\n** Estrogen receptor positive and HER2 negative breast cancer\r\n** Triple negative breast cancerXx_NEWLINE_xXHER2 positive breast cancerXx_NEWLINE_xXPathologically confirmed DCIS of the breastXx_NEWLINE_xXOperable DCIS, suitable for breast conserving surgeryXx_NEWLINE_xXPlans to administer irradiation to the breast onlyXx_NEWLINE_xXMulticentric cancer in the ipsilateral breast as diagnosed by clinical examination, imaging, or pathologic assessment, not amenable to excision with negative margins with a single lumpectomyXx_NEWLINE_xXSynchronous bilateral breast cancer at the time of diagnosisXx_NEWLINE_xXPrior history of breast cancer or in-field radiation in the ipsilateral breastXx_NEWLINE_xXConfirmed diagnosis of inflammatory breast cancer according to international consensus criteria: (1) onset: rapid onset of breast erythema, edema, and/or peau d’orange, and/or warm breast, with or without an underlying breast mass (2) duration: history of such findings no more than 6 months (3) extent: erythema occupying at least 1/3 of whole breast (4) pathology: pathologic confirmation of invasive carcinomaXx_NEWLINE_xXhave a diagnosis of metastatic ER+ breast cancer in patients who received and progressed on at least two lines of endocrine therapy, with one that included a CDK4/CDK6 inhibitor (e.g., palbociclib or ribociclib);Xx_NEWLINE_xXWomen must agree not to breast feed while on studyXx_NEWLINE_xXSubjects are not a candidate for breast conserving surgeryXx_NEWLINE_xXBreast cancer suitable for mandatory baseline core biopsyXx_NEWLINE_xXEarly stage (curable) breast cancerXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Inflammatory breast cancerXx_NEWLINE_xXPatients who had received therapy for metastatic breast cancer (other than that described above)Xx_NEWLINE_xXSubjects must have received no more than 2 prior therapies for metastatic triple-negative breast cancerXx_NEWLINE_xXPatients must have a histologically confirmed HER2 positive breast cancer (by immunohistochemistry [IHC] 3+ or fluorescence in situ hybridization [FISH] ratio >= 2.0)\r\n* Phase I: unresectable locally advanced or metastatic breast cancer\r\n* Phase II: clinical stage 2-3 early stage breast cancerXx_NEWLINE_xXPatients who received tamoxifen or another selective estrogen receptor modulator (SERM) for the prevention or treatment of breast cancer or for other indications (e.g., osteoporosis, prior ductal carcinoma in situ [DCIS]), or who receive aromatase inhibitors for prevention or treatment of breast cancer, are eligible; patients who are hormone-receptor positive and who have received other hormonal agents for the treatment of breast cancer (e.g., Fulvestrant) are also eligible; tamoxifen therapy or other hormonal agents should be discontinued at least 1 week before the patient is started on study therapyXx_NEWLINE_xX(For Cohort A) Archived tissue available pre-screening to confirm FR alpha+ breast cancer. (For Cohort B) ·Confirmed FRalpha+ breast cancer defined as high FRalpha expression: >= 75% of cells having >= 1+ expression, or moderate FRalpha expression: 25%-74% of cells with >= 1+ expressionXx_NEWLINE_xXHistological confirmation of breast cancerXx_NEWLINE_xXExcisional biopsy or lumpectomy for the current breast cancerXx_NEWLINE_xXWomen with pathologically demonstrated breast cancerXx_NEWLINE_xXSubjects may not have had prior systemic chemotherapy regimens administered for treatment of their current breast cancer; however, studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not Food and Drug Administration (FDA) approved for the treatment of the patient’s current breast cancer, are permittedXx_NEWLINE_xXHistologic confirmation of ER+ breast cancerXx_NEWLINE_xXMore than two prior endocrine therapy regimens for the treatment of metastatic ER+ breast cancerXx_NEWLINE_xXHave histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site.Xx_NEWLINE_xXPatients with new or progressive breast cancer metastatic to brain will be eligible provided:Xx_NEWLINE_xXMale breast cancer patients.Xx_NEWLINE_xXTumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: subjects with multifocal/multicentric tumors are eligible). Subject must have (according to TNM 7th edition rules):Xx_NEWLINE_xXNewly diagnosed, biopsy proven cancer of the endometrium, prostate or breastXx_NEWLINE_xXMultifocal disease within the breastXx_NEWLINE_xXPatients for whom radiotherapy for breast cancer is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation)Xx_NEWLINE_xXHas histological confirmation of breast carcinoma.Xx_NEWLINE_xXHas confirmed inflammatory breast cancer by using international consensus criteria:\r\n* Onset: Rapid onset of breast erythema, edema and/or peau d’orange, and/or warm breast, with/without an underlying breast mass.\r\n* Duration: History of such findings no more than 6 months.\r\n* Extent: Erythema occupying at least 1/3 of whole breast.\r\n* Pathology: Pathologic confirmation of invasive carcinoma.Xx_NEWLINE_xXDistant metastasis that involves occurrence of breast cancer outside of locoregional breast and lymph nodes area.Xx_NEWLINE_xXBreast imaging performed prior to study registration as follows:\r\n* Ipsilateral breast – within 12 weeks\r\n* Contralateral breast – within 24 weeksXx_NEWLINE_xXBreast cancer treatment for the currently diagnosed breast cancer including radiation therapy, chemotherapy, targeted therapy, or endocrine therapy prior to study registrationXx_NEWLINE_xXPatient desires breast conserving therapyXx_NEWLINE_xXIf the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancerXx_NEWLINE_xXClinical evidence for a stage T3 or T4 breast cancerXx_NEWLINE_xXClinical evidence of progression of disease > 20% in the breast or new evidence of nodal metastasesXx_NEWLINE_xXInflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d’orange without erythema)Xx_NEWLINE_xXPathologically proven diagnosis of breast cancerXx_NEWLINE_xXClinical T4, N2 or N3, M1 pathologic stages III or IV breast cancerXx_NEWLINE_xXBilateral breast cancerXx_NEWLINE_xXMale breast cancerXx_NEWLINE_xXIf the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancerXx_NEWLINE_xXPathologic or clinical evidence for a stage T4 breast cancerXx_NEWLINE_xXCurrent diagnosis of bilateral breast cancerXx_NEWLINE_xXHistory of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breastXx_NEWLINE_xXNewly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goalXx_NEWLINE_xXPrior systemic therapy for indexed breast cancerXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV breast carcinoma with a previous clinical diagnosis of IBC based on the presence of inflammatory changes in the involved breast, such as diffuse erythema and edema (peau d’orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosisXx_NEWLINE_xXPatients must have histological confirmation of breast carcinomaXx_NEWLINE_xXPatients must have invasive breast cancer (IBC), confirmed according to international consensus criteria:\r\n* Onset: Rapid onset of breast erythema, edema, and/or peau d’orange, and/or warm breast, with or without an underlying breast mass\r\n* Duration: History of such findings no more than 6 months\r\n* Extent: Erythema occupying at least 1/3 of whole breast\r\n* Pathology: Pathologic confirmation of invasive carcinomaXx_NEWLINE_xXHistory of radiotherapy for current breast cancer diagnosisXx_NEWLINE_xXReceived any prior cancer therapy for the breast, uterine, or cervical cancer that is being resected, including progesterone therapy for endometrial cancer patients\r\n* Patients may have had prior therapy for other contra-lateral breast cancerXx_NEWLINE_xXPregnant or need to breast feed during the study periodXx_NEWLINE_xXHave histological confirmation of HER2 positive breast cancerXx_NEWLINE_xXPatients must not have received prior treatment for the current breast cancerXx_NEWLINE_xXStage I-III non-metastatic breast cancer\r\n* Inflammatory breast cancer (T4d) is acceptable\r\n* Patients with oligo-metastatic disease who are being treated with a curative intent as per the treating physician are eligible as wellXx_NEWLINE_xXFor LY3300054 + abemaciclib in HR+, HER- breast cancer:Xx_NEWLINE_xXT4 tumors, known metastatic disease, recurrent disease, inflammatory breast cancer, multicentric disease, and/or synchronous bilateral breast cancerXx_NEWLINE_xXgBRCAm HER2-negative metastatic breast cancer (module 2)Xx_NEWLINE_xXNo prior therapy for current breast cancer and not planning neoadjuvant chemotherapyXx_NEWLINE_xXMust have received no more than 2 lines of chemotherapy for the treatment of breast cancer, and one for the treatment of advanced breast cancerXx_NEWLINE_xXLocally recurrent resectable breast cancerXx_NEWLINE_xXlocalised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy;Xx_NEWLINE_xXSubjects have histologically confirmed adenocarcinoma of the breast - all breast cancer subtypes are allowedXx_NEWLINE_xXHistologic documentation of breast cancer by core needle or incisional biopsyXx_NEWLINE_xXAny other presurgical therapy for breast cancerXx_NEWLINE_xXDiagnosis of inflammatory breast carcinomaXx_NEWLINE_xXDiagnosis of triple-negative or ER-negative breast cancerXx_NEWLINE_xXNo prior treatment with therapeutic intent for breast cancerXx_NEWLINE_xXMetastatic breast cancerXx_NEWLINE_xXInflammatory (T4d) breast cancerXx_NEWLINE_xXInoperable breast cancer even after neoadjuvant treatment as assessed by the treating surgical oncologistXx_NEWLINE_xXDisease that cannot be measured and/or accurately followed by mammogram and/or breast ultrasound and/or dedicated breast MRIXx_NEWLINE_xXBilateral synchronous breast cancerXx_NEWLINE_xXPrevious history of breast cancer (even in the other breast)Xx_NEWLINE_xXEvidence of metastatic/stage 4 breast cancerXx_NEWLINE_xXBreast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric disease preventing resection through a single incision, no pregnant women, and no comorbid conditions precluding surgery)Xx_NEWLINE_xXBreast implant in the breast to be treated (contralateral breast implant is acceptable)Xx_NEWLINE_xXBreast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric or multifocal disease, no pregnant women, and no comorbid conditions precluding surgery)Xx_NEWLINE_xXBreast implant in the breast to be treated with stereotactic body radiation therapy (SBRT)Xx_NEWLINE_xXDocumentation of inflammatory breast cancerXx_NEWLINE_xXEvidence of progressive breast cancer within the last 30 daysXx_NEWLINE_xXMust have progressed on at least 1 prior systemic therapy regimen for the treatment of advanced breast or other non-breast metastatic cancer; there is no upper limit on the number of prior therapiesXx_NEWLINE_xXAt least 10 HER2-negative breast cancer patients will be enrolled in this cohortXx_NEWLINE_xXPatients must have either A) histologic documentation of metastatic or locally advanced breast cancer by core needle or incisional biopsy, or B) history of breast cancer with radiologic evidence of bone-only metastatic diseaseXx_NEWLINE_xXA prior, unrelated, breast cancer is allowedXx_NEWLINE_xXAll stages of breast cancer are eligibleXx_NEWLINE_xXAny prior treatment for the current, newly diagnosed breast cancerXx_NEWLINE_xXInflammatory breast cancer or patients with rapidly progressing metastatic breast cancerXx_NEWLINE_xXEvidence of progressive breast cancer within the last 30 daysXx_NEWLINE_xXLife expectancy >= 52 weeks excluding their diagnosis of breast cancerXx_NEWLINE_xXPatients may not receive concurrent treatment with other investigational or commercial agent(s) for treatment of their breast cancerXx_NEWLINE_xXDiagnosis of inflammatory breast cancerXx_NEWLINE_xXPatients found to have non-gynecologic, uterine, or breast primary at surgeryXx_NEWLINE_xXThe patient must have clinical node negative, stage I breast cancerXx_NEWLINE_xXCOHORT II: The patient must have clinical node negative, stage I breast cancerXx_NEWLINE_xXCOHORT II: Patients must be willing to undergo breast cancer surgery minimally 4, maximally 6 weeks post APBIXx_NEWLINE_xXHormone unresponsive breast cancerXx_NEWLINE_xXHave no inflammatory breast cancersXx_NEWLINE_xXNewly diagnosed clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goalXx_NEWLINE_xXPrior systemic therapy for the indexed breast cancerXx_NEWLINE_xXPatients with bilateral or inflammatory breast cancerXx_NEWLINE_xXWomen who are planning to become pregnant or breast feed during the trialXx_NEWLINE_xXPhysical and emotional ability to undergo baseline and follow-up breast MRIs and serial breast cosmesis analysisXx_NEWLINE_xXPain that developed or worsened since breast cancer diagnosis and is not due to identifiable traumatic event or fractureXx_NEWLINE_xXNo more than two prior cytotoxic chemotherapeutic regimens for metastatic breast cancer; in addition, prior trastuzumab emtansine (TDM-1, Kadcyla) is allowedXx_NEWLINE_xXPatients must have undergone breast-conserving surgeryXx_NEWLINE_xXThe patient must be enrolled on the study within 42 days following the last surgery for breast cancer (lumpectomy, re-excision of margins, or axillary staging procedure)Xx_NEWLINE_xXPatients must have bilateral mammogram and/or breast magnetic resonance imaging (MRI) within 3 months of diagnosis of their breast cancerXx_NEWLINE_xXPatients with synchronous bilateral breast cancers who will be treated with radiotherapy to each breast are eligible, provided such treatment can be performed in a manner that avoids overlap between treatment fields; both sides may be treated with accelerated partial breast irradiation (APBI) if the pathologic eligibility criteria are met for both tumors, or only one side may be treated with APBI if the criteria are met for only one tumorXx_NEWLINE_xXPatients with a history of prior breast cancer in the opposite breast are eligible as long as treatment can be performed without overlapping any prior radiation therapy (RT) fieldsXx_NEWLINE_xXPatients with a history of prior breast cancer in the ipsilateral breast treated with lumpectomy alone (no RT) are eligible as long as the other entry criteria for this study are metXx_NEWLINE_xXMale breast cancerXx_NEWLINE_xXBreast implants; (patients who have implants removed are eligible)Xx_NEWLINE_xXPrior therapy for breast cancerXx_NEWLINE_xXWomen already undergoing neoadjuvant chemotherapy to treat their primary triple negative breast cancerXx_NEWLINE_xXSubjects must be females with a histological diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer clinical stage T0-3, N01 and be candidates for primary resection of this cancer; NOTE: subjects with bilateral cancer are eligible\r\n* Primary tumor stage T0-3 at the time of initial diagnosis and ipsilateral nodes must be N0-1 by clinical evaluation; staging is routinely based on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and TNM Nomenclature for Breast Cancer from American Joint Committee on Cancer (AJCC) Cancer Staging Manual; all breast cancer patients routinely undergo axillary ultrasound to evaluate nodal involvementXx_NEWLINE_xXSubjects must not have received any other breast cancer-specific therapy for the current breast cancer diagnosis prior to registrationXx_NEWLINE_xXAny previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.Xx_NEWLINE_xXPatient must have had a bilateral mammogram prior to NAC unless there is only one breastXx_NEWLINE_xXPatient must have > 1.0 cm residual in-breast cancer and/or clinically positive residual nodal diseaseXx_NEWLINE_xXProgression or recurrence of breast cancer while on or after aromatase inhibitor treatmentXx_NEWLINE_xXA known BRCA-associate genetic mutation OR family history suggesting of a breast or ovarian cancer syndrome, as defined by one or more of the following:\r\n* Personal or known family history of a deleterious (or indeterminate) mutation in the BRCA1, BRCA2, PALB2, or one of the FANC genes\r\n* Personal history of breast cancer and one or more of the following:\r\n** Diagnosed =< 45 years old\r\n** Diagnosed at any age with >= 1 1st, 2nd, or 3rd degree relative with breast cancer =< 50 years old and/or >= 1st, 2nd, or 3rd relative with epithelial ovarian cancer at any age\r\n** Two primary breast cancer with the first diagnosed at =< 50 years old\r\n** Diagnosed =< 60 years old with triple negative breast cancer\r\n** Diagnosed at any age with >= 2 1st, 2nd, or 3rd degree relatives with breast cancer at any age\r\n** Diagnosed at any age with >= 2 1st, 2nd, or 3rd degree relatives with pancreatic cancer or aggressive prostate cancer (Gleason score >= 7) at any age \r\n** 1st, 2nd, or 3rd degree male relative with breast cancer\r\n** Ashkenazi Jewish descent\r\n* Personal history of epithelial ovarian cancer\r\n* Personal history of male breast cancer\r\n* Personal history of pancreatic cancer and >= 2 1st, 2nd, or 3rd degree relatives with breast, epithelial ovarian, pancreatic, or aggressive prostate cancer (Gleason score >= 7) at any ageXx_NEWLINE_xXAddition inclusion for Part A (A6 & A7) Has a histological confirmation of either metastatic breast (ER+ve for Arm A6, 50% ER +ve and 50% HER2+ve metastatic breast cancer patients for Arm A7) or castrate-resistant prostate cancerXx_NEWLINE_xXHave brain metastases secondary to hormone receptor positive breast cancer, NSCLC, or melanoma.Xx_NEWLINE_xXParticipants in Part F must have HR+ breast cancer, NSCLC, or melanoma with leptomeningeal metastases.Xx_NEWLINE_xXSuspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benignXx_NEWLINE_xXNo history of irradiation of the ipsilateral breastXx_NEWLINE_xXNo evidence of other areas worrisome for cancer on physical examination and mammography of the ipsilateral breastXx_NEWLINE_xXA history of irradiation to the ipsilateral breastXx_NEWLINE_xXPatients with proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsyXx_NEWLINE_xXAny previously treated contralateral breast carcinoma or synchronous ipsilateral breast carcinomaXx_NEWLINE_xXPrior radiation therapy for the current breast cancerXx_NEWLINE_xXPregnant or breast feeding; the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancyXx_NEWLINE_xXHistological documentation of advanced solid tumor, other than triple-negative breast cancer (TNBC).Xx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXPrevious systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments); prior treatment for previous breast cancer or other neoplasms is allowed as long as it was completed at least 1 year prior to inclusion into this trial.Xx_NEWLINE_xXPrevious breast cancer and /or radiation in the operated breast.Xx_NEWLINE_xXImplants in the operated breast.Xx_NEWLINE_xXSubareolar location (cancer is directly and completely under the nipple/areolar complex) of breast abnormality.Xx_NEWLINE_xXPart E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancerXx_NEWLINE_xXBreast cancerXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXPresence of breast implantsXx_NEWLINE_xXPrevious breast surgery with the exception of biopsyXx_NEWLINE_xXUndergoing autologous breast reconstructionXx_NEWLINE_xXInclusion Criteria:\n\n          -  • Patient has a non-palpable breast lesion that requires excision\n\n               -  Lesion depth ? 3 cm from the skin surface in the supine position\n\n               -  Patient is scheduled for excision or BCT at a participating institution\n\n               -  Patient is between the ages of 18 and 90 years\n\n               -  Patient is female\n\n               -  Patient is willing and able to comply with all study procedures and be available\n                  to follow-up for the duration of the study\n\n               -  For lesions requiring multiple reflectors for localization, they must allow for\n                  reflectors to be placed ? 1cm from one another relative to the coronal plane\n                  Subject Exclusion Criteria\n\n        An individual who meets any of the following criteria will be excluded from participation\n        in this study:\n\n          -  Patient had a previous ipsilateral breast cancer\n\n          -  Patient has multicentric breast cancer\n\n          -  Patient has Stage IV breast cancer\n\n          -  Patient has been treated with neoadjuvant chemotherapy\n\n          -  Patient is pregnant or lactating\n\n        Exclusion Criteria:Xx_NEWLINE_xXSubjects with confirmed diagnosis of recurrent or metastatic breast cancer based on histopathology examinationXx_NEWLINE_xXPatients with inflammatory breast carcinomaXx_NEWLINE_xXPrior treatment with less than 4 prior endocrine therapies for metastatic breast cancerXx_NEWLINE_xXProgressed after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancerXx_NEWLINE_xXPatients with inflammatory breast cancerXx_NEWLINE_xXThe presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget’s disease is permittedXx_NEWLINE_xXClinically detected or palpable disease prior to biopsy in either breast or ipsilateral axillaXx_NEWLINE_xXMetastatic or locoregionally recurrent HER2-negative breast cancer; resectable disease allowedXx_NEWLINE_xXBilateral or inflammatory breast cancerXx_NEWLINE_xXPatient has metastatic breast cancer that is not suitable for surgery or radiation therapy for local disease control at the time of screening.Xx_NEWLINE_xXA prior, unrelated, breast cancer is allowedXx_NEWLINE_xXPatients planned for pre-operative chemotherapy or those with known metastatic breast cancerXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXCurrent use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six monthsXx_NEWLINE_xXPatients who have received more than 4 weeks of tamoxifen therapy for this malignancy; patient who have received tamoxifen or raloxifene for purposes of chemoprevention (e.g. breast cancer prevention trial or for other past indications (including previous breast cancer) are eligible; tamoxifen or raloxifene therapy will be discontinued at least one month before the patient is enrolled on this studyXx_NEWLINE_xXConcurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancerXx_NEWLINE_xXMales or females with advanced (locoregionally recurrent or metatstatic) breast cancer not amenable to curative therapyXx_NEWLINE_xXPatient has confirmed HER2-negative advanced breast cancer (aBC)Xx_NEWLINE_xXInflammatory breast cancer or tumor with deep adherence or cutaneous invasionXx_NEWLINE_xXBreast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.Xx_NEWLINE_xXDiagnosis of inflammatory breast cancerXx_NEWLINE_xXFor the dose expansion cohort, patients with triple-negative breast cancer may not be BRCA1/2 germline mutation carriersXx_NEWLINE_xXPatients must have the clinical diagnosis of inflammatory breast cancerXx_NEWLINE_xXPatients may have bilateral breast cancer so long as one breast meets criteria for inflammatory breast cancer, and neither breast cancer has received prior therapyXx_NEWLINE_xXEvidence of T4 disease (e.g., involvement of the chest wall, skin, dermal lymphatics, or inflammatory breast cancer)Xx_NEWLINE_xXDocumented mutation of tumor protein 53 (TP53), breast cancer (BRCA)1, BRCA2, or other hereditary cancer syndromesXx_NEWLINE_xXPatients with prior history of stage I-III breast cancer currently without evidence of metastatic disease are eligible if can tolerate further chemotherapy, patients with newly diagnosed synchronous bilateral breast cancers are also eligible if at least one tumor is triple negative (response will be assessed in both breasts if invasive cancer is present in both)Xx_NEWLINE_xXNo prior chemotherapy for this primary breast cancerXx_NEWLINE_xXPatients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancerXx_NEWLINE_xXLocally recurrent breast cancerXx_NEWLINE_xXBreast tumor must be >= 1.5 cm in maximum diameter by clinical or any radiologic measurement, if node negative; if node is positive by biopsy, study participant will be eligible regardless of the size of the breast primary; in case of inflammatory breast cancer, the extent of inflammation/erythema can be used as measurable lesionXx_NEWLINE_xXMultifocal or multicentric breast cancer is allowed if all the lesions are biopsied and are HER2 positive; largest lesion will be assigned the target lesionXx_NEWLINE_xXPrior radiation therapy for breast cancerXx_NEWLINE_xXCandidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeonXx_NEWLINE_xXSubject has hormone-receptor positive metastatic breast cancer with disease progression following antiestrogen therapyXx_NEWLINE_xXSubject has received more than 1 prior line of chemotherapy treatment for metastatic breast cancerXx_NEWLINE_xXPatients with a prior history of contra-lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last 5 yearsXx_NEWLINE_xXPaget’s disease of the breastXx_NEWLINE_xXAll patients must have recurrent or metastatic HER2-positive breast cancer; diagnosed by biopsyXx_NEWLINE_xXPatients with inflammatory breast cancerXx_NEWLINE_xXPatients may not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during protocol treatment; (trastuzumab is allowed in HER2 positive patients)Xx_NEWLINE_xXSubject has inflammatory breast cancerXx_NEWLINE_xXMetastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodesXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXProgressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimusXx_NEWLINE_xXPatients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer; (comorbid conditions should be taken into consideration, but not the diagnosis of breast cancer)Xx_NEWLINE_xXFNA alone to diagnose the breast cancerXx_NEWLINE_xXPatients must not have received any prior treatment of any kind to treat the current breast cancer – including chemotherapy or endocrine therapy; in addition, any history of prior irradiation to the ipsilateral breast is excludedXx_NEWLINE_xXPatients who have received prior lapatinib for metastatic breast cancer will be excludedXx_NEWLINE_xXPatients must not have inflammatory breast cancer and must not have metastatic diseaseXx_NEWLINE_xXPatients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registrationXx_NEWLINE_xXStep 2 Registration must take place within 84 days after definitive surgery; patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomizationXx_NEWLINE_xXPrior treatment with at least two (2) HER2-directed regimens for metastatic breast cancer.Xx_NEWLINE_xXAt least one prior regimen of chemotherapy in the setting of metastatic breast cancer; no upper limit on the number of prior endocrine regimens for metastatic breast cancer, however no more than 6 chemotherapeutic regimens may have been given in the metastatic settingXx_NEWLINE_xXBreast cancer must be HER2-negative.Xx_NEWLINE_xXPrior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions.Xx_NEWLINE_xXHER2 positive breast cancerXx_NEWLINE_xXActive inflammatory breast cancerXx_NEWLINE_xXdiagnosis of HR+, HER2+ breast cancer (BC)Xx_NEWLINE_xXPhase 1 patients (breast or ovarian cancer)Xx_NEWLINE_xXPhase 2 patients (breast or ovarian cancer)Xx_NEWLINE_xXReceived either one or two prior systemic treatments for metastatic breast cancer and have documented disease progression on or after the most recent therapyXx_NEWLINE_xXHER2+ patients must have received pertuzumab and TDM-1 (ado-trastuzumab emtansine) prior to trial enrollment; unless deemed ineligible for these therapies, and with the exceptions listed below:\r\n* Patients with metastatic breast cancer who have not received prior pertuzumab are eligible if: heavily pretreated prior to Food and Drug Administration (FDA) approval of pertuzumab (6/8/2012) for first-line treatment of HER2+ metastatic breast cancer (MBC)\r\n* Patients with metastatic breast cancer who have not received ado-trastuzumab emtansine are eligible if: heavily pretreated prior to FDA approval of ado-trastuzumab emtansine (2/22/2013) for the treatment of patients with HER2+ MBC who previously received trastuzumab and a taxane separately or in combinationXx_NEWLINE_xXTriple Negative Breast CancerXx_NEWLINE_xXnewly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapyXx_NEWLINE_xXPatient with inflammatory breast cancer at screeningXx_NEWLINE_xXMetastatic Breast Cancer: Human Epidermal Growth Factor Receptor 2 - negative (HER2(-)) recurrent Metastatic Breast Cancer:Xx_NEWLINE_xXSubject has inflammatory breast cancerXx_NEWLINE_xXBilateral breast cancers are allowed as long as both cancers are HER2-positive; however, only the primary cancer’s status requires central reviewXx_NEWLINE_xXHave not previously received therapy for the treatment of unresectable locally-advanced breast cancer or metastatic breast cancerXx_NEWLINE_xXHas pathologically documented breast cancer that:Xx_NEWLINE_xXCentrally assessed Ki-67, pRB, and Cyclin D1 status assessed preferably on post-neoadjuvant residual invasive disease of the breast, or if not possible, of residual nodal invasion or core biopsy. In case of bilateral breast cancer, tumor tissue of both sides needs to be assessable.Xx_NEWLINE_xXEstimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer.Xx_NEWLINE_xXdefinitively treated, stage I/II ER+ breast cancerXx_NEWLINE_xXConcurrent treatment with hormone replacement therapy is permitted at the discretion of the treating physician; patients who have been taking hormonal/hormone blocking agents for breast cancer or breast cancer prevention or other indication are eligible; use of anti-hormonal agents (tamoxifen, medroxyprogesterone, aromatase inhibitors) is permitted at the discretion of the treating physician; documentation of concurrent medications is requiredXx_NEWLINE_xXProven diagnosis of metastatic breast cancer (MBC).Xx_NEWLINE_xXExceptions are breast cancer in the other breast.Xx_NEWLINE_xXUncommon or rare subtypes of breast cancer.Xx_NEWLINE_xXCompletely resected unilateral or bilateral primary carcinoma of the breastXx_NEWLINE_xXClinical evidence of distant metastases per practice guidelines for breast cancer;Xx_NEWLINE_xXInflammatory breast cancer or tumor with deep adherence or cutaneous invasion;Xx_NEWLINE_xXHistologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancerXx_NEWLINE_xXSubjects with Inflammatory breast cancer.Xx_NEWLINE_xXPart B: Breast CancerXx_NEWLINE_xXCohort 1: Participants must have triple negative breast cancer.Xx_NEWLINE_xXRadiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancerXx_NEWLINE_xXRadiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an AI, or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancerXx_NEWLINE_xXPrior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancerXx_NEWLINE_xXThe subject has AR+ breast cancerXx_NEWLINE_xXThe subject has a history of a non-breast cancer malignancy with the following exceptions:Xx_NEWLINE_xXDocumented Breast Cancer Gene (BRCA) germline mutation testing.Xx_NEWLINE_xXHistological or cytological confirmation of ER+ and/or PR+ breast cancerXx_NEWLINE_xXPatients who received more than one chemotherapy line for advanced breast cancer.Xx_NEWLINE_xXPatients who wish to breast-feed during treatmentXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXHistological confirmation of breast carcinomaXx_NEWLINE_xXMetastatic breast cancer patients currently on hormonal therapy as first- or second-line are not permittedXx_NEWLINE_xXnewly diagnosed advanced/metastatic breast cancer, treatment naïveXx_NEWLINE_xXnewly diagnosed advanced/metastatic breast cancer at diagnosis that progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor)Xx_NEWLINE_xXPatient with inflammatory breast cancer at screening .Xx_NEWLINE_xXConfirmed diagnosis of ER positive breast cancerXx_NEWLINE_xXPatient has HER2-negative breast cancerXx_NEWLINE_xXPatients who currently have inflammatory breast cancer at screening.Xx_NEWLINE_xXPatients who received any prior hormonal anti-cancer therapy for advanced breast cancer, except for ? 14 days of tamoxifen or NSAI ± goserelin for advanced breast cancer prior to randomization.Xx_NEWLINE_xXHave inflammatory breast cancerXx_NEWLINE_xXAre currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancerXx_NEWLINE_xXAre currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancerXx_NEWLINE_xXHER2-positive breast cancerXx_NEWLINE_xXParticipant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapyXx_NEWLINE_xXParticipants with multicentric (multiple tumors involving more than 1 quadrant) or bilateral breast cancerXx_NEWLINE_xXProven multicentric carcinoma (tumors in different quadrants of the breast, or tumors separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsyXx_NEWLINE_xXSubjects with HER-2 expressing stage I – III breast cancer with residual disease in the breast or axillary nodes post-neoadjuvant chemotherapyXx_NEWLINE_xX12 patients with breast cancer for whom 5 FU chemotherapy is the standard treatmentXx_NEWLINE_xXConfirmed diagnosis of HR+/HER2- breast cancerXx_NEWLINE_xXIf multifocal breast cancer, then it must be able to be resected through a single lumpectomy incisionXx_NEWLINE_xXPatient is not a candidate for breast conservationXx_NEWLINE_xXConfirmed diagnosis of ER positive breast cancerXx_NEWLINE_xXFemale subjects ? 21 years of age with histological or cytological diagnosis of breast carcinoma.Xx_NEWLINE_xXSubjects with more than 2 events of disease progression after the development of metastatic breast cancer.Xx_NEWLINE_xXPatients with biopsy-confirmed breast cancerXx_NEWLINE_xXMiller-Payne response in the breast of 0-25.Xx_NEWLINE_xXParticipant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancerXx_NEWLINE_xXParticipant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancerXx_NEWLINE_xXMetastatic triple negative breast cancer (TNBC)Xx_NEWLINE_xXConcomitant active malignancy other than ER+ breast cancer.Xx_NEWLINE_xXNewly diagnosed (cohort 2) stage IV metastatic ER+HER2- breast cancer histologically proven per current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines; allow up to 30 days prior use of endocrine therapy +/- CDK4/6 inhibitors for treatment of metastatic ER+ breast cancerXx_NEWLINE_xXInflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d’orange without erythema)Xx_NEWLINE_xXAn excisional biopsy of this breast cancerXx_NEWLINE_xXPatients must not have received any prior treatment for current or newly diagnosed breast cancerXx_NEWLINE_xXWilling to undergo breast core biopsies as required by the study protocolXx_NEWLINE_xXPatients with recurrent breast cancer; patients with contralateral second primary breast cancers are eligibleXx_NEWLINE_xXPatients with metastatic breast cancerXx_NEWLINE_xXHave a diagnosis of HR+, HER2- breast cancer.Xx_NEWLINE_xXParticipants with radiologic/objective evidence of breast cancer recurrence or progression while on or within 6 months after the end of adjuvant treatment with an AI, or progression while on or within 1 month after the end of prior AI treatment for locally advanced or metastatic breast cancerXx_NEWLINE_xXPatient desire to undergo breast surgeryXx_NEWLINE_xXThe cancer enhances on breast MRI imagingXx_NEWLINE_xXNewly diagnosed, biopsy-proven stage 0-II breast cancerXx_NEWLINE_xXPlanning to undergo breast-conserving surgeryXx_NEWLINE_xXPreference for mastectomy instead of breast-conserving surgeryXx_NEWLINE_xXHistory of ipsilateral breast cancerXx_NEWLINE_xXPrior history of ipsilateral breast cancerXx_NEWLINE_xXPaget’s disease of the breastXx_NEWLINE_xXBreast implants (patients who have had implants removed are eligible)Xx_NEWLINE_xXParticipants must have histologically confirmed invasive breast cancer that is metastatic or unresectable locally advanced; histological documentation of metastatic/recurrent breast cancer is not required if there is unequivocal evidence for recurrence of the breast cancerXx_NEWLINE_xX=< 90 days from the patient’s most recent breast surgery for this breast cancerXx_NEWLINE_xXHave been diagnosed with noninvasive or invasive (stage 1, 2, or 3A) breast cancer, colon cancer, lymphoma, or ovarian cancerXx_NEWLINE_xXInflammatory/inoperable breast cancer.Xx_NEWLINE_xXPrior endocrine therapy for breast cancer.Xx_NEWLINE_xXNormal mammogram of the contralateral breast within the past 12 months, defined as no new suspicious calcifications or other abnormal findings warranting a breast biopsyXx_NEWLINE_xXEvidence of metastatic breast cancerXx_NEWLINE_xXWomen must agree not to breast feedXx_NEWLINE_xXPatients must not have had prior ipsilateral breast-conserving surgery or total mastectomy and be eligible for neoadjuvant treatmentXx_NEWLINE_xXPatients must not have inflammatory breast cancer (T4d) and must not have metastatic breast cancer (stage IV disease)Xx_NEWLINE_xXProgression on at least 2 lines of anti-HER2-targeted therapies for metastatic breast cancer (MBC)Xx_NEWLINE_xXWomen must not breast-feed while taking the study medicationsXx_NEWLINE_xXMale and female participants with locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. Participants with inflammatory breast cancer must be able to have a core needle biopsyXx_NEWLINE_xXHave a diagnosis of HR+, HER2- breast cancerXx_NEWLINE_xXMen with metastatic or unresectable breast cancer are eligibleXx_NEWLINE_xXMetastatic breast cancer patients who are hormone receptor positive at baseline must be hormone refractory or have indications for emergent treatment with chemotherapy (e.g., visceral crisis)Xx_NEWLINE_xXPHASE II: Patients must have the clinical diagnosis of inflammatory breast cancer as evidenced by the onset of signs and symptoms noted below within a 6 month time-period:\r\n* Erythema of the breast\r\n* Edema of the skin of the breast\r\n* Enlargement of the breastXx_NEWLINE_xXMore than 2 prior lines of chemotherapy for metastatic breast cancer.Xx_NEWLINE_xXBreast > 800 grams or < 100 grams in predicted weight; “breast” includes the breast tissue and in cases where the patient already has cosmetic breast implants, the additional breast implant mass; the sum total must be > 100 g and < 800 gXx_NEWLINE_xXSurgeon’s opinion at the time of surgery that the subject’s well-being (e.g. significant comorbidities, intraoperative findings of a higher stage cancer or other independent acute health problems) would be compromised; if the contralateral breast is undergoing a nipple-sparing mastectomy with reconstruction as well, then the contralateral breast can be studied so long as there is no compromise to any element of their careXx_NEWLINE_xXHER2-positive breast cancerXx_NEWLINE_xXNo more than 9 weeks (63 days) may elapse between definitive breast surgery (or the last surgery if additional resection required for breast cancer) and randomizationXx_NEWLINE_xXPatients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancerXx_NEWLINE_xXPartial breast irradiation must be scheduled to begin less than 71 days from the last breast surgical procedureXx_NEWLINE_xXPatients with squamous or sarcomas of the breastXx_NEWLINE_xXPatients with breast implants are excluded.Xx_NEWLINE_xXPatients have histological confirmation of breast carcinomaXx_NEWLINE_xXPatients who have received a previous HER2 breast cancer vaccineXx_NEWLINE_xX=< 90 days between the planned treatment start date and the patient’s most recent breast surgery for this breast cancerXx_NEWLINE_xXIf a patient has HER2-positive breast cancer, herceptin and pertuzumab will be given along with taxane therapyXx_NEWLINE_xXAny stage invasive breast cancer provided the primary breast tumor size is >= 1 cmXx_NEWLINE_xXPrior treatment for the currently diagnosed breast cancerXx_NEWLINE_xXPatients must have the clinical diagnosis of inflammatory breast cancer as evidenced by the onset of all signs and symptoms noted below within a 6 month time-period:\r\n* Erythema of the breast\r\n* Edema of the skin of the breast\r\n* Enlargement of the breastXx_NEWLINE_xXPrior therapy for the treatment of breast cancer is not allowedXx_NEWLINE_xXLocally recurrent resectable breast cancerXx_NEWLINE_xXHER2-positive breast cancerXx_NEWLINE_xXPatients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasonsXx_NEWLINE_xXBreast cancer patients must be currently on adjuvant aromatase inhibitorsXx_NEWLINE_xXNo prior treatment for metastatic breast cancerXx_NEWLINE_xXPatients who have received prior hormonal or any other systemic therapy for metastatic breast cancer.Xx_NEWLINE_xXFamily history of familial cancer syndromes (leukemia, breast, ovarian, colorectal, etc.)Xx_NEWLINE_xXPatients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this studyXx_NEWLINE_xXPathologically confirmed diagnosis of breast cancer with documented progressive diseaseXx_NEWLINE_xXParticipants must have histologically confirmed invasive breast cancer that is metastatic or unresectable locally advanced; histological documentation of metastatic/recurrent breast cancer is not required if there is unequivocal evidence for recurrence of the breast cancerXx_NEWLINE_xXMust have a documented deleterious Breast Cancer Gene BRCA1 or BRCA2 germline mutation.Xx_NEWLINE_xXPrior taxane therapy for metastatic breast cancer.Xx_NEWLINE_xXSubjects with advanced stage breast cancerXx_NEWLINE_xXSubjects with prior history of cancer in the ILT treated breastXx_NEWLINE_xXSubjects with recurrent breast cancerXx_NEWLINE_xXUndergoing concurrent neoadjuvant therapies for breast cancerXx_NEWLINE_xXPart D: Breast cancer that is advanced and/or metastaticXx_NEWLINE_xXPart G: Breast Cancer that is not only advanced and/or metastatic but also hormone receptor positiveXx_NEWLINE_xXParticipants must have completed definitive breast surgery (mastectomy or breast-conserving) +/- reconstructive surgery with referral for definitive chest wall radiation therapy; patients with breast reconstruction are eligible if it determined by the referring or treating radiation oncologist that plan would be suboptimal without manipulation of breast implants; for patients without reconstruction, they must meet eligibility by having unfavorable cardiac anatomy defined as >= 5% of the heart receives >= 20 Gy and/or left anterior descending (LAD) receives >= 20 Gy with conventional planning; participants do not need to have measurable disease; most patients will not have measurable disease at the time of treatmentXx_NEWLINE_xXPrior allergic reaction to trastuzumab for the treatment of metastatic breast cancerXx_NEWLINE_xXPatients with breast cancer must have had at least one prior chemotherapy regimen for metastatic disease; additionally, patients with breast cancer must have received prior tamoxifen and/or aromatase inhibitor therapy (if post-menopausal) with at least one hormonal regimen in the metastatic setting; patients with HER2+ breast cancer must have progressed after at least one prior HER2-directed regimen (trastuzumab, lapatinib) for metastatic disease\r\n* All other patients must have disease that has progressed following at least one line of standard therapy; prior therapy with tamoxifen is allowedXx_NEWLINE_xXUnifocal breast cancer (no evidence of gross multifocal disease, multicentric, or bilateral disease)Xx_NEWLINE_xXPatients with multicentric gross disease defined as tumors in different quadrants of the breast or tumor separated by at least 4 cm or other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy or biopsyXx_NEWLINE_xXPatients who have received agents that modulate or downregulate the estrogen receptor for breast cancer prevention (e.g. tamoxifen, raloxifene, fulvestrant) or bone health (raloxifene) are eligible if they were on treatment for at least 6 months, did not have a diagnosis of breast cancer on the medication, and have discontinued the agents 6 months prior to study registrationXx_NEWLINE_xXThe participant has previously received endocrine therapy for breast cancer prevention (tamoxifen or raloxifene or aromatase inhibitors).Xx_NEWLINE_xXTreatment with breast conserving surgeryXx_NEWLINE_xXIf the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed at least one month prior to study registration and the patient must have no evidence of disease for this prior non-breast cancerXx_NEWLINE_xXHistory of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breastXx_NEWLINE_xXCurrent diagnosis of bilateral breast cancerXx_NEWLINE_xXRecurrent breast cancerXx_NEWLINE_xXBreast cancer with metastasis to skeletal sites onlyXx_NEWLINE_xXPatients who have received prior chemotherapy for their original breast cancer treatment are still eligibleXx_NEWLINE_xXErbB-2 positive locally recurrent or metastatic breast cancerXx_NEWLINE_xXBeen treated for early breast cancer with standard of care duration of trastuzumab.Xx_NEWLINE_xXCurrent carcinoma of the breastXx_NEWLINE_xXAdvanced breast cancer with positive BRCA1 or BRCA2 statusXx_NEWLINE_xXHave histological confirmation of breast carcinoma with a clinical diagnosis of IBC based on presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d’orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required at diagnosisXx_NEWLINE_xXEvidence of metastatic breast cancer following a standard tumor staging work-upXx_NEWLINE_xXEvidence of inflammatory breast cancerXx_NEWLINE_xXSubjects unfit for breast and/or axillary surgery (complete fixation of tumor, skin infiltration, erythema of the breast, and/or ulceration)Xx_NEWLINE_xXBreast cancer: Patients with Her-2 negative breast cancer after anthracycline and taxane based chemotherapy.Xx_NEWLINE_xXIf the subject has ER+ breast cancer, prior therapy must have included at least 1 hormonal therapyXx_NEWLINE_xXPart 2 includes target expressing NSCLC, ovarian or breast cancer patientsXx_NEWLINE_xXPrior endocrine therapy for any histologically-confirmed cancer is not allowed; prior endocrine therapy that was administered >= 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowedXx_NEWLINE_xXAny other neoadjuvant therapy for breast cancer (i.e., treatment with any other anti-cancer agent besides letrozole [10-21 days] before surgical resection of the primary breast tumor)Xx_NEWLINE_xXPatients with histologically or cytologically confirmed locally advanced breast cancer that is refractory to chemotherapy or other therapeutic agents or with a history of breast cancer with new evidence of a local recurrence (defined as a chest wall or breast recurrence and/or nodal recurrence); the diagnosis will be made based on clinical and pathologic featuresXx_NEWLINE_xXEvidence of inflammatory cancer (clinical presentation of skin erythema involving more than one third of the breast or pathological evidence of dermal lymphatic involvement)Xx_NEWLINE_xXPrevious excisional biopsy of the breast cancerXx_NEWLINE_xXCancer in a patient with a known inherited susceptibility mutation in breast cancer (BRCA)1 or BRCA2Xx_NEWLINE_xXMulticentric breast cancer (two foci of known cancer in the breast separated by greater than 5 cm, or in separate quadrantsXx_NEWLINE_xXAny prior breast cancerXx_NEWLINE_xXWith advanced breast cancer whose disease was refractory to previous letrozole or anastrozoleXx_NEWLINE_xXPatients must have histologically proven breast cancer with metastatic disease to the brainXx_NEWLINE_xXPatients who are receiving concomitant systemic therapy for breast cancerXx_NEWLINE_xXPatients with metastatic breast cancerXx_NEWLINE_xXCohort 1: Has triple negative breast cancer, is considered for cohort 1 participation, and received prior anthracycline therapyXx_NEWLINE_xXCandidate for curative breast cancer surgery (Cohort 1 or 2)Xx_NEWLINE_xXBreast cancer metastatic to the pleura that extends outside of the pleura requiring immediate therapyXx_NEWLINE_xXTreatment with biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entryXx_NEWLINE_xXPatient has T1c-T3, any N, M0, operable breast cancerXx_NEWLINE_xXMulticentric breast cancerXx_NEWLINE_xXPrimary breast cancer that is suitable for baseline core biopsy.Xx_NEWLINE_xXInflammatory breast cancer.Xx_NEWLINE_xXRecurrent ipsilateral breast cancerXx_NEWLINE_xXBreast cancer eligible for primary surgeryXx_NEWLINE_xXBreast cancerXx_NEWLINE_xXBreast cancerXx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXHistologically verified breast cancer with distant metastases (metastatic breast cancer)Xx_NEWLINE_xXConcurrent anti-cancer treatment, except anti-hormonal therapy for subjects with hormone receptor positive breast cancerXx_NEWLINE_xXPrior or concomitant treatment for advanced breast cancer.Xx_NEWLINE_xXFor subjects with breast cancer:Xx_NEWLINE_xXBreast cancer in BRCA1 or BRACA2 positive ovarian cancer patientsXx_NEWLINE_xXNo current evidence of breast cancerXx_NEWLINE_xXRecurrent breast cancer or other malignancyXx_NEWLINE_xXGroup 2: Post-menopausal women with advanced stage estrogen receptor positive breast cancer who are candidates for exemestane or fulvestrantXx_NEWLINE_xXPreviously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesionXx_NEWLINE_xXPart 2 includes advanced triple negative breast cancer patients.Xx_NEWLINE_xXPathologically confirmed diagnosis of breast cancer (central confirmation is not required)Xx_NEWLINE_xXHistologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease o Patients with breast cancer overexpressing HER2 are not eligible.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed breast carcinoma with a clinical diagnosis of IBC based on the presence of inflammatory changes in the involved breast, such as diffuse erythema and edema (peau d’orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosisXx_NEWLINE_xXPrior reconstructive breast surgery, breast augmentation, mastopexy or reduction mammoplastyXx_NEWLINE_xXPre-operative treatment with induction chemotherapy for breast cancerXx_NEWLINE_xXTreated CIS of the breast or cervixXx_NEWLINE_xXER+/HER2+ breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D), advanced or metastatic ER+ positive breast cancer that has an AKT1 gene mutation (Part E) or advanced or metastatic ER+ positive breast cancer that has a PTEN gene mutation (Part F).Xx_NEWLINE_xXPatients must have been treated by breast conserving surgery (BCS) or mastectomyXx_NEWLINE_xXPatients treated with neoadjuvant chemo or endocrine therapy for breast cancerXx_NEWLINE_xXHas received prior capecitabine treatment for advanced breast cancerXx_NEWLINE_xXHas received more than 1 prior antiangiogenic agent for breast cancerXx_NEWLINE_xXHormone-refractory metastatic breast cancer defined as disease progression within 6 months from starting most recent hormonal therapyXx_NEWLINE_xXEarly stage breast cancer (T1c-3, cN0-3, cM0)Xx_NEWLINE_xXSubjects with prior skin changes consistent with inflammatory breast carcinoma are eligible.Xx_NEWLINE_xXBreast carcinoma for medical reasons not being resectedXx_NEWLINE_xXPrevious (required active treatment within 5 years) or concomitant malignancy except basal cell cancer, in situ carcinoma of the cervix, or contralateral breast cancer. Subjects with a prior contralateral breast malignancy can be included if they did not receive any chemotherapy.Xx_NEWLINE_xXHas a condition which may interfere with the hyperthermia portion of the trial such as: functioning cardiac pacemaker; metal plates, rods or prosthesis of the chest wall, breast reconstruction with implants, severe numbness and/or tingling of the chest wall or breast, skin grafts and/or flaps on the breast or chest wall.Xx_NEWLINE_xXPrior cytotoxic chemotherapy for recurrent or metastatic breast cancer (phase II portion)Xx_NEWLINE_xXPatient with inflammatory breast cancerXx_NEWLINE_xXFor the dose expansion cohort, patients with triple-negative breast cancer may not be breast cancer 1/2 (BRCA1/2) germline mutation carriersXx_NEWLINE_xXFor breast cancer patients only, endocrine therapies are allowed (such as aromatase inhibitors, but not current tamoxifen. Prior tamoxifen is permitted with a 30 day wash out period)Xx_NEWLINE_xXHave a diagnosis of breast cancer and be chemotherapy naive; NOTE: prior methotrexate for non-cancerous conditions is allowedXx_NEWLINE_xXPatients receiving ongoing hormonal therapy for breast cancer must be on the same hormonal agent for at least 3 months prior to study registration and plan to continue for the duration of the study (9 months)Xx_NEWLINE_xXBreast cancer for which patient is receiving endocrine therapy must have been histologically-proven stage I-III, endocrine-responsive (i.e., estrogen and/or progesterone receptor positive, according to local definition of positive, determined using immunohistochemistry [IHC]), and treated with curative intent\r\n* Note:\r\n** Patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible\r\n** Patient with invasive breast cancer or synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) during pregnancy are eligible\r\n** Patients with breast cancer 1/2, early onset (BRCA1/2) mutations are eligible\r\n** Patients could have received neo/adjuvant chemotherapy, or other systemic therapy (e.g., neo/adjuvant human epidermal growth factor receptor 2 [HER2]-targeted therapy) according to institutional policy and patient’s desireXx_NEWLINE_xXPatient must be premenopausal at breast cancer diagnosis, as determined locally and documented in patient record; (Note: it is understood that patients’ menopausal status may be unclear at the time of study enrollment)Xx_NEWLINE_xXPost-menopausal patients at breast cancer (BC) diagnosis, as determined locallyXx_NEWLINE_xXPatients with current local, loco-regional relapse and/or distant metastatic breast cancerXx_NEWLINE_xXRecurrent breast cancer or history of prior breast radiation therapyXx_NEWLINE_xXBreast cancer requiring bilateral breast/chest wall radiation therapyXx_NEWLINE_xXMale breast cancer patientsXx_NEWLINE_xXPatients who report a baseline pain score > 3, unrelated to a breast procedureXx_NEWLINE_xXLocally recurrent or metastatic breast cancerXx_NEWLINE_xXDiagnosis of other active malignancy; prior treated malignancies in addition to breast cancer are acceptableXx_NEWLINE_xXHistologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)Xx_NEWLINE_xXBreast cancer diagnosis, stage 1, 2, or 3 (solely for patients enrolled at Montefiore Medical Center, St. Barnabas, Jacobi Medical Center, and North Central Bronx)Xx_NEWLINE_xXFOCUS GROUPS: \r\n* Breast cancer patient, stage 1,2, or 3,\r\n* Currently undergoing treatment with chemotherapy and/or radiation;\r\n* Food insecure;\r\n* Language spoken: English or SpanishXx_NEWLINE_xXDiagnosed with metastatic breast cancer, caregiver to patient with metastatic breast cancer (MBC) who is enrolled in this study, or MBC providerXx_NEWLINE_xXMen and women with recurrent or advanced breast cancerXx_NEWLINE_xXDiagnosed with breast, colorectal, or prostate cancer (stages I-III)Xx_NEWLINE_xXHas a breast cancer recurrence, metastasis, or another interval cancer diagnosis following the breast cancer (excluding non-melanoma skin cancer)Xx_NEWLINE_xXPathologically confirmed breast cancerXx_NEWLINE_xXWomen at high risk of breast cancer due to one or more of the following:\r\n* Carry deleterious mutations in the breast cancer, early onset (BRCA)1, BRCA2, phosphatase and tensin homolog (PTEN), tumor protein p53 (TP53), serine/threonine kinase 11 (STK11), or cadherin-1 (CDH1) genes\r\n* Previous diagnosis of lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)\r\n* Lifetime risk of 20% or greater as calculated by the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool or the Tyrer-Cuzick International Breast Cancer Intervention Study (IBIS) Risk Assessment ToolXx_NEWLINE_xXWomen histologically diagnosed with carcinoma of the breastXx_NEWLINE_xXMulti-centric disease (histologically diagnosed cancer in two different quadrants of the breast)Xx_NEWLINE_xXImplants in the operated breastXx_NEWLINE_xXInflammatory or metaplastic breast cancerXx_NEWLINE_xXPrior ipsilateral breast cancer radiotherapy will be excluded; prior contralateral breast cancer therapy within 2 years will also be excludedXx_NEWLINE_xXAdvanced or metastatic breast cancerXx_NEWLINE_xXBREAST CANCER COHORT:Xx_NEWLINE_xXAre in breast cancer remission with no detectable disease presentXx_NEWLINE_xXEvidence of breast cancer recurrence or metastasisXx_NEWLINE_xXCurrent recurrence of their breast cancer (BC) (local or distant)Xx_NEWLINE_xXHave been diagnosed with localized breast or prostate (stages 1-2) or colorectal cancer (stage 1-3)Xx_NEWLINE_xXNo prior therapy for current breast cancerXx_NEWLINE_xXOperable breast cancer\r\n* Patients who are planned to undergo neo-adjuvant chemotherapy are eligible as long as they consent to an additional breast biopsy following the dietary intervention immediately prior to starting chemotherapyXx_NEWLINE_xXPATIENT: Confirmed medical diagnosis of breast or thoracic cancer regardless of stage and followed at DCC for managementXx_NEWLINE_xXEvidence of recurrent breast cancer at the time of enrollmentXx_NEWLINE_xXFemales who have been diagnosed with breast cancer and currently taking toremifeneXx_NEWLINE_xXPatients with metastatic breast cancerXx_NEWLINE_xXPlanned additional surgery to the surgical breast or axilla in the next year (exception would be minor surgery to breast but not axilla such as simple tissue expander replacement or lumpectomy)Xx_NEWLINE_xXMetastatic breast cancerXx_NEWLINE_xXNew breast cancer diagnosisXx_NEWLINE_xXHistory of recurrent breast cancer (with a prior history of chemotherapy)Xx_NEWLINE_xXStage IV breast cancer diagnosis (metastases remote from the breast)Xx_NEWLINE_xXPrior genetic counseling or testing for hereditary breast/ovarian cancerXx_NEWLINE_xXRecent diagnosis of breast cancer with pending surgery as primary treatment for breast cancerXx_NEWLINE_xXMust not have had history of breast cancer, breast surgery, radiation to the chest wallXx_NEWLINE_xXLymphedema Group: > 3 months (mths) post-breast cancer treatmentXx_NEWLINE_xXNo Lymphedema Group: > 3 mths post- breast cancer treatmentXx_NEWLINE_xXFemale breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy).Xx_NEWLINE_xXHaving received chemotherapy as part of their primary therapy for breast cancer.Xx_NEWLINE_xXBeing within 1 month (before or after) of surgery for breast cancer (including breast reconstructive surgery). Smaller surgical procedures such as implant exchange are not exclusionary.Xx_NEWLINE_xXHave surgery for breast cancer or breast reconstructive surgery planned during the initial 6 month study period. Smaller surgical procedures such as implant exchange are not exclusionary.Xx_NEWLINE_xXDiagnosed with any stage breast, GI, or lung cancerXx_NEWLINE_xXConfirmed first diagnosis of stage IV breast cancer or a recurrent diagnosis of metastatic breast cancer (MBC) (i.e., spread to distant organs), any time since diagnosisXx_NEWLINE_xXAny medical treatment for breast cancer will be allowedXx_NEWLINE_xXAdditionally, patients that have a high risk of breast cancer and are pursuing prophylactic mastectomies (for example BRCA mutation carriers) will also be consideredXx_NEWLINE_xXSubjects will not have breast surgery as a portion of their breast cancer careXx_NEWLINE_xXSubjects with breast implants or a history of prior breast implantsXx_NEWLINE_xXSubjects that have had prior breast reduction surgeryXx_NEWLINE_xXPatient must be an Asian American who has had a breast cancer diagnosis in the past 5 yearsXx_NEWLINE_xXThose who are in treatment or not in treatment, but who were diagnosed with breast cancer within the past 5 years will be includedXx_NEWLINE_xXPrimary diagnosis of breast cancer (initial or recurrence) within the last two yearsXx_NEWLINE_xXRecurrence of breast cancerXx_NEWLINE_xXHave persistent pain (unrelated to aromatase inhibitors or chemotherapy-induced peripheral neuropathy) for at least 3 months following treatment for breast cancerXx_NEWLINE_xXPhase I: Breast oncology team members at Massachusetts General Hospital (MGH) Cancer Center will be eligible if they are either physicians or nurse practitioners primarily involved in the care of breast cancer patients and with direct experience with metastatic breast cancer patientsXx_NEWLINE_xXBreast cancer survivors treated with chemotherapy with no evidence of disease with treatment completed at least six months prior to study participation with or without current endocrine therapyXx_NEWLINE_xXHave a diagnosis of stage I-III female breast cancer or colorectal cancer within the past 5 years; bilateral or multiple primary breast cancers are permitted; individuals who have had more than one type of cancer (e.g., both breast and melanoma) are permitted as long as the breast (or colorectal) diagnosis meets the other criteria and primary treatment for any cancer is not ongoingXx_NEWLINE_xXYOUNG BREAST CANCER SURVIVORS (YBCS): Breast cancer (Stages 0-III) diagnosisXx_NEWLINE_xXYBCS: Breast cancer diagnosis age ? 45 yearsXx_NEWLINE_xXPast cancer; patients will be excluded if they have ever been diagnosed with cancer (including ductal breast carcinoma in situ [DCIS]/lobular breast carcinoma in situ [LCIS]) prior to the breast cancer for which the present course of AIs is being prescribed; however, patients will be eligible if their have a history of: nonmetastatic, non-melanotomous skin cancerXx_NEWLINE_xXPatients with metastatic breast cancer are not eligible to participateXx_NEWLINE_xXPatients who have a diagnosis of breast cancerXx_NEWLINE_xXPatients on anti-hormonal therapies (e.g., anti-estrogens for breast cancer) or other maintenance therapies will be eligible.Xx_NEWLINE_xXPatients scheduled for breast surgeryXx_NEWLINE_xXDiagnosed with breast, GYN, GI, GU, or thoracic cancerXx_NEWLINE_xXReceived first breast surgery of total or partial mastectomy within the previous 9 monthsXx_NEWLINE_xXReport average pain >= 3 during the first nine months after surgery on the Breast Cancer Pain QuestionnaireXx_NEWLINE_xXHistory of prior breast cancer surgeryXx_NEWLINE_xXBreast cancer survivorsXx_NEWLINE_xXHave breast cancer stage 0-IIIAXx_NEWLINE_xXNo histological confirmation of breast cancerXx_NEWLINE_xXPatients with a recurrent breast cancer diagnosisXx_NEWLINE_xXMemorial Sloan Kettering Cancer Center (MSK) histologically confirmed early-stage operable breast cancer (patients with HER-2 negative or HER-2 positive breast cancer are eligible)Xx_NEWLINE_xXA diagnosis of local regional breast cancer (stage 0-IIIa)Xx_NEWLINE_xXWomen who are known to be positive for the breast cancer (BRCA) mutationXx_NEWLINE_xXHad a previous diagnosis of breast cancer (any type or stage) as confirmed by official medical recordsXx_NEWLINE_xXHas been diagnosed with early-stage breast cancerXx_NEWLINE_xXWomen previously diagnosed with stage 0-IIIA breast cancerXx_NEWLINE_xXHistologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)Xx_NEWLINE_xXPatients should be followed in Stefanie Spielman Comprehensive Breast Center (SSCBC) High Risk Breast ClinicXx_NEWLINE_xXPHASE I AIM 3.2: Malignant diagnosis in breast, gynecologic (GYN), genitourinary (GU) cancer at any stageXx_NEWLINE_xXHave been diagnosed with stage 0-III breast cancer; bilateral or multiple primary breast cancers are permittedXx_NEWLINE_xXHave a previous diagnosis of breast cancerXx_NEWLINE_xXBreast cancer at age 50 or belowXx_NEWLINE_xXBilateral breast cancerXx_NEWLINE_xXTriple negative breast cancerXx_NEWLINE_xXHave 2 or more blood relatives diagnosed with breast cancerXx_NEWLINE_xXHave any blood relatives diagnosed with bilateral breast cancerXx_NEWLINE_xXA first degree relative diagnosed with breast cancer below age 50Xx_NEWLINE_xXHave a known cancer gene mutation (such as breast cancer 1/2, early onset [BRCA 1/2])Xx_NEWLINE_xXHave any male relatives diagnosed with breast cancerXx_NEWLINE_xXNew diagnosis of breast cancer stage 1-2Xx_NEWLINE_xXStage 3 or 4 breast cancer or any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma)Xx_NEWLINE_xXHistologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer diagnosis, then the most recent diagnosis)Xx_NEWLINE_xXDecided to have blood drawn for breast cancer, early onset gene (BRCA) 1/2 syndrome testingXx_NEWLINE_xXIn early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancerXx_NEWLINE_xXHas been diagnosed with breast cancer, currently in remission or eradicatedXx_NEWLINE_xXBelongs to a breast cancer support groupXx_NEWLINE_xXMeet National Comprehensive Cancer Network (NCCN) criteria for consideration of genetic testing for hereditary breast cancerXx_NEWLINE_xXPrimary diagnosis of breast cancer within the last three yearsXx_NEWLINE_xXWomen who have undergone a total mastectomy or breast-conserving surgery for primary breast cancer +/- chemotherapy, +/- radiotherapyXx_NEWLINE_xXPHASE I: Has a first, primary diagnosis of unilateral stage 0, 1, 2, or 3a breast cancer (patients with bilateral breast cancer will be excluded from participation)Xx_NEWLINE_xXPHASE II: Completed initial surgical consult with breast cancer surgeon at Cancer Institute of New Jersey (CINJ)/Massachusetts General Hospital (MGH)/Memorial Sloan Kettering Cancer Center (MSKCC) and is considering CPM, regardless of the surgical treatment of their primary breast cancer (lumpectomy/mastectomy)Xx_NEWLINE_xXPHASE II: Has a first, primary diagnosis of unilateral stage 0, 1, 2, or 3a breast cancerXx_NEWLINE_xXDiagnosis of stage IV breast cancer or recurrent metastatic breast cancerXx_NEWLINE_xXAny woman with biopsy proven left breast DCIS or invasive cancer who has undergone a lumpectomy and who requires whole breast irradiation to the breast alone (and not to any nodal regions) as per the treating radiation oncologistXx_NEWLINE_xXPrevious radiation to the ipsilateral breastXx_NEWLINE_xXMust have completed local therapy for their breast cancerXx_NEWLINE_xXNo local or distant recurrence of their breast cancerXx_NEWLINE_xXSurvivors of breast cancer that have not received either breast surgery or radiation therapyXx_NEWLINE_xXCompleted treatment for stage 1-3 breast cancer at least two months but not more than 24 months prior to enrollment.Xx_NEWLINE_xXReceiving treatment for another malignancy other than breast cancerXx_NEWLINE_xXDiagnosis of metastatic breast cancerXx_NEWLINE_xXWomen with stage 1-3 breast cancer who are within first two rounds of chemotherapy OR women who have stage 4 breast cancer at initial diagnosis and are initiating first line chemotherapy; note: women with stage 4 breast cancer must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1Xx_NEWLINE_xXDiagnosis of recurrent breast cancerXx_NEWLINE_xXPatients with metastatic breast cancerXx_NEWLINE_xXStage I-III gynecologic cancer (any site) or breast cancerXx_NEWLINE_xXPrior treatment of gynecologic or breast cancer with chemotherapyXx_NEWLINE_xXCompletion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the pastXx_NEWLINE_xXProspective study: individuals will have pathologically confirmed breast cancer (stages I-III)Xx_NEWLINE_xXMetastatic breast or other cancerXx_NEWLINE_xXMetastatic breast or other cancerXx_NEWLINE_xXHave been diagnosed with non-metastatic breast cancer (stages 0-III)Xx_NEWLINE_xXHave completed curative treatment for breast cancerXx_NEWLINE_xXPathologically confirmed breast cancerXx_NEWLINE_xXWomen with a history of cancer, any stage, with breast or gynecologic cancerXx_NEWLINE_xXDiagnosed with breast cancerXx_NEWLINE_xXPatients who have been surgically treated for breast cancer more than 3 months; healing usually occurs within 3 months of surgical treatment for cancerXx_NEWLINE_xXAre diagnosed with primary breast cancer (BC) (stages I-III)Xx_NEWLINE_xXNode-negative left breast cancerXx_NEWLINE_xXConfirmed diagnosis of primary breast, cervical, endometrial, or ovarian cancerXx_NEWLINE_xXStage 0-IIIA breast cancer survivors and their partnerXx_NEWLINE_xXAll the female breast cancer survivors will be at least two months from receiving cancer treatment (surgery, adjuvant therapy or radiation) and within three years from completing cancer treatment, except for tamoxifen/aromatase inhibitorsXx_NEWLINE_xXMale breast cancer survivorsXx_NEWLINE_xXStage 1A – 2B breast cancer diagnosisXx_NEWLINE_xXPathologically confirmed HER2-positive breast cancerXx_NEWLINE_xXDiagnosis of breast cancerXx_NEWLINE_xXIntact breast (not surgically absent)Xx_NEWLINE_xXThe patient must be deemed an appropriate candidate for breast conserving therapy (i.e. not pregnant, never had radiation to the treated breast, breast size would allow adequate cosmesis after volume loss from partial mastectomy)Xx_NEWLINE_xXUnable to fit into the breast immobilization device due to breast size or other anatomical reasonXx_NEWLINE_xXSubjects should have breast and axillary imaging with breast magnetic resonance imaging (MRI) (preferred) or breast and axillary ultrasound (US) within 4 weeks prior to treatment initiationXx_NEWLINE_xXSubject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancerXx_NEWLINE_xXSubjects with inflammatory breast cancerXx_NEWLINE_xXStage I and II breast cancer patients undergoing active radiation therapyXx_NEWLINE_xXPatients eligible for the study will be newly-diagnosed female breast cancer patients with stage I-ll invasive breast cancer who are eligible for and considering either mastectomy or breast-conserving surgery (BCS) with radiation, and who may be eligible for adjuvant systemic treatmentXx_NEWLINE_xXHave a history of breast cancerXx_NEWLINE_xXAdult women (both pre-menopausal and post-menopausal women are eligible) and with a history of breast cancer or with an increased risk for breast cancer on current treatment with tamoxifen or an aromatase inhibitor with the presence of vaginal dryness or dyspareunia of sufficient severity to make the subject patient desire therapeutic interventionXx_NEWLINE_xXNo prior chemotherapeutic treatment for any malignancy other than breast cancerXx_NEWLINE_xXHistologically confirmed stage I-III colorectal or breast cancer who have undergone curative-intent complete surgical resection and completed all adjuvant cytotoxic chemotherapy and radiation (if indicated) at least 2 months prior to enrollment; breast cancer patients on hormonal therapy or trastuzumab only therapy and colorectal cancer patients on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in Cancer and Leukemia Group B [CALGB] 80702 receiving only celecoxib/placebo) are eligibleXx_NEWLINE_xXDiagnosis of HER2-positive breast cancerXx_NEWLINE_xXPatients scheduled to undergo paclitaxel chemotherapy for breast cancerXx_NEWLINE_xXPathologic documentation of breast cancerXx_NEWLINE_xXHistory of a diagnosis of breast cancerXx_NEWLINE_xXHave been diagnosed with breast cancerXx_NEWLINE_xXBreast cancer diagnosis within past 5 yearsXx_NEWLINE_xXSubjects with a diagnosis of non-inflammatory breast cancer or carcinoma in situXx_NEWLINE_xXSubjects must be prescribed and scheduled for “conventional fractionated” RT without concurrent chemotherapy; bolus and intensity modulated radiation therapy (IMRT) are permitted; lymph node irradiation (i.e., internal mammary nodes, supraclavicular nodes, axillary nodes, etc) as part of their prescribed radiation therapy are permitted; conventional fractionated radiation therapy regimens eligible for study are described below:\r\n* Minimal (min) total dose: whole breast: 44 gray (Gy); breast boost: 10 Gy; tumor bed = whole breast +/- boost: 50.0 Gy; lymph nodes: 45 Gy\r\n* Maximal (max) total dose: whole breast: 50.4 Gy; breast boost: 20 Gy; tumor bed = whole breast +/- boost: 66.0 Gy; lymph nodes: 50.4 Gy\r\n* Min dose per fraction: whole breast: 1.8 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 1.8 Gy; lymph nodes: 1.8 Gy\r\n* Max dose per fraction: whole breast: 2.0 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 2.0 Gy; lymph nodes: 2.0 Gy\r\n* Min # of fractions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy\r\n* Max # of fractions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 Gy\r\n* Min # of sessions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy\r\n* Max # of sessions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 GyXx_NEWLINE_xXSubjects with bilateral breast cancer are not eligibleXx_NEWLINE_xXSubjects with breast reconstruction prior to RTXx_NEWLINE_xXPresence of unhealed surgical wounds in chest or breast region and/or breast infectionXx_NEWLINE_xXHave a confirmed diagnosis of breast cancer; participants can have had more than one primary cancer diagnosis in the pastXx_NEWLINE_xXCompleted treatment for breast cancer (except hormonal therapies) within 12 months.Xx_NEWLINE_xXAre not within 12 months of completing treatment for breast cancer (except hormonal therapies) at the time of recruitment;Xx_NEWLINE_xXWomen with breast cancer who plan to undergo radiation therapy to the breast or chest wallXx_NEWLINE_xXWomen with inflammatory breast cancer as evidenced by clinical assessmentXx_NEWLINE_xXWomen with breast cancer involving the skinXx_NEWLINE_xXLymphedema in an arm as a result of surgery, chemotherapy, and/or radiation therapy for breast cancer per breast surgeon or medical oncologistXx_NEWLINE_xXHave a diagnosis of breast cancer, any stage.Xx_NEWLINE_xXPatients who have not undergone autologous tissue breast reconstruction and intend to undergo implant only breast reconstructionXx_NEWLINE_xXPatients with prior radiation to the breast/chest wall of the ipsilateral breastXx_NEWLINE_xXWomen initially diagnosed with breast cancer by histological tissue diagnosis in 2003 or laterXx_NEWLINE_xXWomen with a history of breast cancer (currently without malignant disease) or women who have no history of breast cancer but who wish to avoid estrogen due to a perceived increased risk of breast cancerXx_NEWLINE_xXPatients must not have symptoms or signs of benign or malignant breast disease (e.g., bloody or clear nipple discharge, breast lump) based on physician physical exam or self breast exam; patients with breast pain are eligible as long as other criteria are metXx_NEWLINE_xXPatients must not currently have breast enhancements (e.g., implants or injections)Xx_NEWLINE_xXDo not have a history of breast cancerXx_NEWLINE_xXWomen who are undergoing screening breast MRI as per standard of care for high-risk breast cancer screeningXx_NEWLINE_xXWilling to donate left-over tissue if patient undergoes a breast biopsy and/or breast surgeryXx_NEWLINE_xXParticipants who have received breast radiation within 1 year prior to screening breast MRIXx_NEWLINE_xXDiagnosed with breast cancer at age 45 or youngerXx_NEWLINE_xXHave at least 2 relatives with breast cancer on the same side of the family, one of which is =< 50 years of ageXx_NEWLINE_xXHave one male relative with breast cancerXx_NEWLINE_xXPrior breast cancer or DCIS diagnosisXx_NEWLINE_xXINCLUSION - PATIENT: Women presenting for breast cancer screening with either MRI or mammography: Group 1 will consist of women who present for screening breast MRI:\r\n* Asymptomatic for breast disease\r\n* Presenting for routine breast cancer screening with MRIXx_NEWLINE_xXRecommendation for breast biopsy has been madeXx_NEWLINE_xXHave a first degree relative with a history of breast or colorectal cancerXx_NEWLINE_xXBreast implantsXx_NEWLINE_xXRecent prior breast surgery or breast biopsy or cyst aspiration within the prior 12 monthsXx_NEWLINE_xXWomen and men with symptomatic breast lump (either by palpation or imaging) ORXx_NEWLINE_xXPatients with known breast cancerXx_NEWLINE_xXPatients with known diagnosis of breast cancerXx_NEWLINE_xXPatients who have had a lumpectomy for breast cancer within 18 months prior to the studyXx_NEWLINE_xXHave one or more first or second degree relatives with breast cancer, with at least one under the age of 60Xx_NEWLINE_xXHave a prior diagnosis of T1 or T2 breast cancer diagnosed within the last 10 yearsXx_NEWLINE_xXHave breast density assessed as >= 25% on a prior mammogram (Boyd 1995)Xx_NEWLINE_xXWomen with bilateral breast implants or tram flap reconstructionXx_NEWLINE_xXWomen with a current mammographic or clinical breast exam mass which is suspicious for breast cancer (ACR class IV), and malignancy has not been ruled outXx_NEWLINE_xXInclusion Criteria:\n\n        A. Subjects whose most recent (within 18 months) prior mammogram interpreted as\n        heterogeneously dense (ACR BI-RADS Breast Density C) or extremely dense (ACR BI-RADS Breast\n        Density D) breast tissue.\n\n        AND\n\n        B. Subjects who are asymptomatic and scheduled to undergo routine screening mammography.\n\n        OR\n\n        C. Subjects scheduled for image-guided needle biopsy as a result of findings obtained\n        during standard of care imaging modalities (mammography, ultrasound and/or MRI) performed\n        at the clinical site that participates in the study.\n\n        Exclusion Criteria:\n\n          1. Male by birth.\n\n          2. Individual is less than 40 and greater than 70 years old.\n\n          3. Contraindication to bilateral mammography or MRI.\n\n          4. Subjects who are unable to read, understand and execute the informed consent\n             procedure.\n\n          5. Subjects who have had mammography, ultrasound or MRI examination performed on the day\n             of the study prior to RI8 scan.\n\n          6. Subjects who are pre-menopausal and are between the 14th and 28th day after the start\n             of the menstrual cycle\n\n          7. Subjects who have significant existing breast trauma.\n\n          8. Subjects who have undergone lumpectomy/mastectomy.\n\n          9. Subjects who have undergone breast reduction or breast augmentation.\n\n         10. Subjects who have undergone any other type of breast surgery, including surgical\n             biopsy.\n\n         11. Subjects who have large breast scar / breast deformation\n\n         12. Subjects who have undergone a breast needle biopsy within the 6-week period prior to\n             their intended enrollment into the study.\n\n         13. Subjects who have a temperature > 100° F (37.8C) degrees on the day of the RI8\n             imaging.\n\n         14. Subjects who are pregnant or lactating.\n\n         15. Subjects with known Raynaud's Disease.\n\n         16. Subjects with known Mastitis.\n\n         17. Subjects diagnosed with epileptic seizures.\n\n         18. Subjects with weight > 135kg (~300 Lbs.).\n\n         19. Subjects who are claustrophobic or have physical limitations that do not allow them to\n             sit in the system chair for the required imaging session.\n\n         20. Subjects with implanted pacemaker/defibrillator, implanted venous access device\n             (portacath) or other implanted devices.\n\n         21. Subject with kidney failure\n\n         22. Subject with known allergy to gadolinium\n\n         23. Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the\n             past two year)\n\n         24. Inmates (45 CFR 46.306) or mentally disabled individuals.\n\n         25. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the\n             purpose of planning cancer therapy).\n\n         26. Subjects currently participating in another investigational clinical study.\n\n         27. Subject scheduled for a biopsy due to suspicious symptomatic lump\n\n         28. Subjects who participated in the Validation Phase will not be able to participate in\n             the Testing PhaseXx_NEWLINE_xX2) Patients must have a diagnosis of breast cancer for which they must not have received or been scheduled for primary breast surgery at time of project intervention, and must be eligible for surgical resection (i.e. Stage I-III).Xx_NEWLINE_xXNewly diagnosed breast cancer patientsXx_NEWLINE_xXPatient must be asymptomatic for breast disease and undergoing routine screeningXx_NEWLINE_xXPatient must have no known breast cancer (DCIS or invasive cancer), not currently undergoing treatment for breast cancer, or planning surgery for a high risk lesion (atypical ductal breast hyperplasia [ADH], atypical lobular breast hyperplasia [ALH], lobular breast carcinoma in situ [LCIS], papilloma, radial scar)Xx_NEWLINE_xXPatient must not be taking chemoprevention for breast cancerXx_NEWLINE_xXPatient must not have undergone breast ultrasound within 12 months prior to randomizationXx_NEWLINE_xXPatient must not have previously had molecular breast imaging (MBI, multiplexed ion beam imaging [MIBI])Xx_NEWLINE_xXPatient must agree to not undergo screening ultrasound (of breast) for the duration of the 1 year study periodXx_NEWLINE_xXPatient must not be suspected of being at high-risk for breast cancer, as defined by the American Cancer Society (ACS) breast MR screening recommendations (lifetime risk of >= 20-25%)Xx_NEWLINE_xXBREAST CANCER SURVIVORS: Has histologically-confirmed, first-time breast cancer (stage I-IIIB);Xx_NEWLINE_xXBREAST CANCER SURVIVORS: Has no prior exposure to neurotoxic chemotherapy or radiation treatment;Xx_NEWLINE_xXBREAST CANCER SURVIVORS: Will be receiving either paclitaxel (Taxol or generic) either (a) weekly (~80-100mg/m^2) or (b) every other week (i.e., dose-dense) (~175 mg/m^2) Taxol for the treatment of breast cancer ORXx_NEWLINE_xXBREAST CANCER SURVIVORS: Will be receiving an anthracycline and cyclophosphamide (AC) as a part of their initial treatment for breast cancer with plans to receive Taxol either weekly (~80-100mg/m^2) or every other week (i.e., dose-dense) (~175 mg/m^2);Xx_NEWLINE_xXPatients with breast implantsXx_NEWLINE_xXWomen considered at increased risk for developing breast carcinoma (those with a lifetime risk of > 15% due to family history, genetic predisposition, prior radiation therapy to the chest, prior biopsy showing a high risk lesion, or personal history of breast cancer) that are being screened with breast MRIXx_NEWLINE_xXWomen with breast implantsXx_NEWLINE_xXStage I-III female breast cancer (including inflammatory and newly diagnosed, or locally recurrent but not metastatic breast cancer being treated with curative intent)Xx_NEWLINE_xXMust be at increased risk for breast cancer, defined as at least one of the following four criteria:\r\n* Having had a prior biopsy demonstrating atypical hyperplasia, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS)\r\n* A Gail Model Risk of >= 1.66% over 5 years\r\n* A strong family history of breast and/or ovarian cancer which is defined as at least one of the following:\r\n** One first-degree relative with breast cancer before the age of 50 years\r\n** One first degree relative with bilateral breast cancer\r\n** Two or more first-degree relatives with breast cancer\r\n** One first degree relative and two or more second or third degree relatives with breast cancer\r\n** One first-degree relative with breast cancer and one or more relatives with ovarian cancer\r\n** Two second or third degree relatives with either breast cancer and one or more with ovarian cancer\r\n** One second or third degree relative with breast cancer and two or more with ovarian cancer\r\n** Three or more second or third degree relatives with breast cancer\r\n* Known breast cancer (BRCA)1 or BRCA2 mutation carrier providing that the woman has \r\n** Met with a genetic counselor to review genetic testing results, and \r\n** Has been offered the opportunity to undergo prophylactic mastectomy and oophorectomyXx_NEWLINE_xXMammograms must be read as not suspicious for breast cancer (American College of Rheumatology [ACR] class I-III); subjects with a class IV mammogram may be enrolled once they have been evaluated by a breast surgeon and there is no evidence of invasive malignancyXx_NEWLINE_xXBilateral breast implants or autologous breast flap reconstructionXx_NEWLINE_xXPrevious treatment for breast cancer including chemotherapy, endocrine therapy and radiotherapy; women with prior ductal breast carcinoma in situ (DCIS) who were treated with surgery only and whose treatment ended >= 2 years prior to enrollment are eligible for the trialXx_NEWLINE_xXLess than 40 years if 5-year breast cancer Gail risk is >= 1.66%Xx_NEWLINE_xXPrior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions)Xx_NEWLINE_xXHistory of prior breast cancer treated within the past two years; patients completing all breast cancer-specific treatment over two years prior to the current diagnosis are eligibleXx_NEWLINE_xXNewly diagnosed stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancyXx_NEWLINE_xXWomen must be considered at high risk for breast cancer based on family history (first or second degree relative diagnosed with breast cancer under the age of 60), prior precancerous biopsy or a 5-year Gail model risk estimate of >= 1.7% or 10-year Tyrer-Cuzick risk of 2 x population risk as listed in the modelXx_NEWLINE_xXWomen with bilateral breast implants or tram flap reconstructionXx_NEWLINE_xXWomen with current mammographic or clinical breast exam mass which is suspicious for breast cancer and malignancy has not been ruled outXx_NEWLINE_xXBETA/USABILITY TESTING: Utilizing the breast cancer surveillance consortium risk calculator, women will have high 5-year (> 1.66%) risk for breast cancer and high breast density (heterogeneously or extremely dense)Xx_NEWLINE_xXPrior history of breast cancer, breast/chest wall/axillary radiation therapyXx_NEWLINE_xXBilateral breast cancer or planned bilateral mastectomyXx_NEWLINE_xXAt high risk of developing breast cancer defined by one or more of the following: Gail model lifetime risk > 20%, a history of deleterious BRCA1/2 mutation or mantle radiation, a history of ductal cancer in situ, or a history of high risk premalignant breast lesion.Xx_NEWLINE_xX>= 6 months from all previous breast cancer treatment (including endocrine therapy)Xx_NEWLINE_xXParticipants must have adequate accessible breast tissue as determined by the treating physician, consisting of one breast unaffected by invasive cancer, which has not been radiated; a history of benign core biopsy of this breast will be permittedXx_NEWLINE_xXPrior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions) or combination of breast radiation and surgery involving both breastsXx_NEWLINE_xXPrior history or evidence of metastatic breast cancerXx_NEWLINE_xXCurrent use or < 6 months since use of selective estrogen receptor modulator (SERMS) or aromatase inhibitors or any other investigational treatment for breast cancer prevention or therapyXx_NEWLINE_xXCOHORT B: No prior diagnosis of breast cancer but at high risk for development of breast cancer and participating in HSC 4601Xx_NEWLINE_xXDiagnosis of breast cancerXx_NEWLINE_xXPathologically confirmed diagnosis of HER2 positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy)Xx_NEWLINE_xXPrevious history or current diagnosis of breast cancerXx_NEWLINE_xXPatients referred for risk reduction mastectomy (ex. breast cancer (BRCA) or other high-risk gene mutations, strong family history of breast cancer, history of lobular breast carcinoma in situ (LCIS), atypical ductal breast hyperplasia (ADH), atypical lobular breast hyperplasia (ALH) and those with ductal breast carcinoma in situ (DCIS) undergoing bilateral mastectomy or prophylactic contralateral mastectomy)Xx_NEWLINE_xXPatients with an implant in the sampled breastXx_NEWLINE_xXModerate risk of developing breast cancer based on either by having at least one of following:\r\n* First or second degree relative with breast cancer age 60 or younger\r\n* Prior breast biopsy\r\n* Prior RPFNA atypia\r\n* Estimated mammographic density of 25% or higher\r\n* Gail 5-year risk of > 1.7% (as calculated by the National Cancer Institute [NCI] Breast Cancer Risk Assessment Tool) or a 5 year Gail Risk of 2X that for age group; and/or\r\n* International Breast Cancer Intervention Study (IBIS) Breast Cancer Risk Evaluation 10-year relative risk of > 2X that for the population for age groupXx_NEWLINE_xXWomen at high-risk of breast cancer, as defined by one of the following:\r\n* Cytologically confirmed atypical hyperplasia\r\n* Cytologically confirmed lobular breast carcinoma in situ (LCIS)\r\n* Being a carrier for at least one of the following mutations:\r\n** BRCA1 and/or BRCA2\r\n** TP53\r\n** PTEN\r\n** CDH1\r\n** PALB2\r\n** ATM\r\n** CHEK2\r\n* Predicted lifetime risk of breast cancer > 20% based on family history\r\n* Predicted 10-year risk of breast cancer of >= 2.31%\r\n* Predicted 5-year risk of breast cancer >= 1.67%Xx_NEWLINE_xXClinical breast exam interpreted as benign (not suspicious for cancer) at Memorial Sloan Kettering (MSK)Xx_NEWLINE_xXBilateral breast implantsXx_NEWLINE_xXMammogram performed or reviewed by an Ohio State University (OSU) radiologist at the Stefanie Spielman Comprehensive Breast Center or the James Cancer Hospital within the six months prior to study enrollment that are not suspicious for breast cancer (American College of Radiology [ACR] class I-III); subjects with a class IV mammogram may be entered following a negative biopsyXx_NEWLINE_xXMust be willing to undergo fine needle aspiration of the contralateral breast for breast adipose tissue at 0, 3, 6, 9 and 12 months of the study and breast epithelial tissue samples at 0, 6 and 12 months of studyXx_NEWLINE_xXSubjects with breast implantsXx_NEWLINE_xXSubjects with insufficient breast adipose tissue and/or parenchymal breast tissue/breast density for adequate FNA sampling as determined by clinical examination and/or mammographyXx_NEWLINE_xXElevated risk of breast cancer as defined by at least one of the following categories and have declined tamoxifen and/or raloxifene therapy:Xx_NEWLINE_xXMust have at least one breast available for imaging and biopsy. A previously irradiated breast (i.e., for resected DCIS) is not evaluable for breast imaging or biopsy. a. Allow for submission of core needle breast material for future use.Xx_NEWLINE_xXBilateral breast implants. Prior breast reduction surgery is allowed.Xx_NEWLINE_xXHistological confirmation of breast cancerXx_NEWLINE_xXBreast conserving surgery and indications for whole breast radiotherapyXx_NEWLINE_xXRecurrent breast cancerXx_NEWLINE_xXThe presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget's disease is permittedXx_NEWLINE_xXWomen with skin diseases (psoriasis, eczema) on the breastXx_NEWLINE_xXHistory of prior breast cancer-specific therapy within the previous 2 years; previous unilateral radiation in women scheduled for mastectomy of the contralateral side is allowedXx_NEWLINE_xXA 1st or 2nd degree relative with breast cancer diagnosed under the age of 60Xx_NEWLINE_xXMultiple prior breast biopsies regardless of histologyXx_NEWLINE_xXIf undergoing annual screening mammography, must have been performed within 9 months prior to baseline RPFNA and interpreted either as not suspicious for breast cancer or with any supplementary imaging performed and interpreted as not suspicious for breast cancerXx_NEWLINE_xXBreast exam interpreted as normal (not suspicious for cancer)Xx_NEWLINE_xXBilateral breast implantsXx_NEWLINE_xXWomen seeking an RRSO or RRS at MSK, including breast cancer 1 (BRCA 1)/breast cancer 2 (BRCA2) mutation carriers and women with a strong family history of breast and or/ovarian cancerXx_NEWLINE_xXBreast carcinoma:Xx_NEWLINE_xXSubjects who are at high risk for breast cancer will be considered for participation in the studyXx_NEWLINE_xXDefinition of a high risk population: \r\n* The study population will consist of women with a relative risk of developing breast cancer that is at least > 2 x that of the general population for their age group on the basis of any of the following:\r\n** Have a known genetic mutation associated with hereditary breast cancer (including breast cancer [BRCA]1, BRCA2, tumor protein [p]53, etc.)\r\n** One or more first degree relatives with breast cancer, with at least one under the age of 60\r\n** Two or more second degree relatives with breast cancer, with at least one under the age of 50\r\n** Prior biopsy diagnosing atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ in the last 10 years\r\n** Have a Gail Risk Assessment (which is based on age, race, age of menarche, age of first live birth, number of first degree relatives with breast cancer, number of breast biopsies, and presence of high risk histology on any biopsies) that is considered high risk compared to the general population: \r\n*** 5 year Gail >= 1.7 or\r\n*** 10 year Gail >= 3.4%\r\n** Prior diagnosis of T1 or T2 breast cancer diagnosed within the last 10 years, without chemotherapy or antiestrogen therapy for > six months and >= 2 months since completion of radiation therapy, when applicableXx_NEWLINE_xXBarriers to fine needle aspiration sampling of breast adipose, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose tissue for adequate fine needle aspiration (FNA) sampling as determined by clinical examination and/or mammogramXx_NEWLINE_xXSubjects must have had a normal mammogram or breast MRI within 9 months prior to registration; NOTE: subjects must also have a normal breast exam on the day of the pre-intervention studiesXx_NEWLINE_xXSubjects who have been diagnosed with a prior cancer at any site (other than breast cancer) may participate as long as they have been off medical therapy for at least 12 months prior to registrationXx_NEWLINE_xXSubjects with prior breast cancer must be off all systemic therapy (including endocrine agents) for at least 2 years prior to registrationXx_NEWLINE_xXSubjects with Inflammatory breast cancer.Xx_NEWLINE_xXBreast cancer patients in the expansion cohort must be hormone sensitive or have refractory diseaseXx_NEWLINE_xXPatients with inflammatory breast cancer are eligible for the escalation phase of the mastectomy cohortXx_NEWLINE_xXInflammatory breast cancer patients are ineligible, except in the escalation phase of the mastectomy cohortXx_NEWLINE_xXSubject has a pacemaker present in the field of radiation or quadrant of the breast cancerXx_NEWLINE_xXSubject has biopsy-proven multifocal breast cancerXx_NEWLINE_xXSubject has multi-centric breast cancerXx_NEWLINE_xXSubject has a history of recurrent breast cancer in the ipsilateral breastXx_NEWLINE_xXSubject has BRCA 1 or 2 mutations. Note: Testing will only be required for Subjects presenting with bilateral breast cancer; testing is not required for unilateral cancersXx_NEWLINE_xXLife expectancy of at least 5 years, excluding diagnosis of breast cancer (comorbid conditions should be taken into consideration, but breast cancer diagnosis is not a consideration)Xx_NEWLINE_xXBilateral mammogram =< 90 days prior to date of surgery; Note: for patients undergoing more than 1 breast operation, this is the date of the first breast surgery for breast cancer treatmentXx_NEWLINE_xXBreast implants at time of diagnosis; Note: patients who have had implants previously removed prior to diagnosis are eligibleXx_NEWLINE_xXPatients with known breast cancer (BRCA) mutations; patients who are not tested or whose testing result is not returned at the time of registration are not excluded from registering to this studyXx_NEWLINE_xXPatients may enroll within 10 years of breast cancer diagnosis, as long as there is a plan for at least 1 more year of adjuvant endocrine therapyXx_NEWLINE_xXMammogram negative for breast cancer within the 12 months preceding the time of registration for women >= 50 years of ageXx_NEWLINE_xXHave breast implantsXx_NEWLINE_xX>= 6 months from all previous breast cancer treatment (including surgery for invasive cancer, chest wall radiotherapy, chemotherapy, trastuzumab and endocrine therapy)Xx_NEWLINE_xXParticipants must have adequate accessible breast tissue as determined by the treating physician, consisting of one breast unaffected by invasive cancer, which has not been radiated; a history of prior pre-invasive breast cancer or benign biopsy of this breast will be permittedXx_NEWLINE_xXPrior history or evidence of metastatic breast cancerXx_NEWLINE_xXPrior history of contralateral (unaffected) breast augmentation with breast implant placementXx_NEWLINE_xXWomen who are receiving endocrine therapy for breast cancer treatment or chemoprevention including tamoxifen, letrozole, anastrozole, fulvestrant, or exemestane at the time of screeningXx_NEWLINE_xXPatients must be at elevated risk for breast cancer based on strong family history or a history of breast biopsy documenting atypical hyperplasia anytime in the past; for this study strong family history is defined as having:\r\n* 1 first-degree (parent, offspring, sibling) relative =< 50 years old when diagnosed with breast cancer, or\r\n* >= 2 first-degree relatives of any age when diagnosed with breast cancer, or\r\n* >= 2 second-degree (aunts, uncles, grandparents, grandchildren, nieces, nephews, or half-siblings) maternal or paternal relatives diagnosed with breast cancer and at least 1 diagnosed at =< 50 years of ageXx_NEWLINE_xXDiagnosis of stage I-IIIA breast cancer within past 5 years (confirmed by medical record review)Xx_NEWLINE_xXTreatment with total mastectomy and axillary dissection; or breast-sparing surgical removal of cancer with clear macroscopic margins and axillary dissection; followed by adjuvant breast radiationXx_NEWLINE_xXPatients may be enrolled between 1-6 months from completion of standard primary breast cancer therapiesXx_NEWLINE_xXClinical and/or radiographic evidence of residual or persistent breast cancerXx_NEWLINE_xXKnown recurrence of breast cancer (local, regional or distant) at any time prior to study entry.Xx_NEWLINE_xXPatients must have breast or ovarian cancerXx_NEWLINE_xXBreast cancer completely excised, or patient receiving neoadjuvant therapy prior to surgeryXx_NEWLINE_xXBilateral breast malignancy or suspicious mass in opposite breastXx_NEWLINE_xXInflammatory breast malignancyXx_NEWLINE_xXPatients must be undergoing breast conserving therapyXx_NEWLINE_xXT4 tumors including inflammatory breast cancerXx_NEWLINE_xXNo patients with bilateral breast cancerXx_NEWLINE_xXNo patients with known deleterious mutations in breast cancer (BRCA) genesXx_NEWLINE_xXNo patients scheduled to receive partial breast irradiation following breast conserving surgeryXx_NEWLINE_xXPatients with biopsy-proven breast cancerXx_NEWLINE_xXPatients with a prior history of ipsilateral breast cancerXx_NEWLINE_xXOperable breast cancer treated with NAC undergoing either breast conservation or total mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a complete imaging response, which is defined as no residual tumor enhancementXx_NEWLINE_xXProhibited treatments and/or therapies:\r\n* Prior history of breast cancer surgery and/or radiotherapyXx_NEWLINE_xXAny woman who has completed or is nearing completion of neoadjuvant therapy for breast cancer and is scheduled for a post-NAT breast MRI and mammogramXx_NEWLINE_xXParticipants must be candidates for definitive local therapy with breast conserving therapy or deemed as potential candidates following NAT (this takes into account tumor to breast size ratio appropriate for breast cancer therapy [BCT], and the ability to undergo standard radiation therapy post-operatively)Xx_NEWLINE_xXParticipants with inflammatory breast cancer or multi-centric diseaseXx_NEWLINE_xXDiagnosed with a Breast Imaging Reporting and Data System (BI-RADS) score of 4 or higher breast abnormality greater than 1cm in sizeXx_NEWLINE_xXPrescribed neoadjuvant chemotherapy for breast cancerXx_NEWLINE_xXParticipants must be candidates for definitive local therapy with breast conserving therapy (this takes into account tumor to breast size ratio appropriate for breast-conserving surgery [BCS], and the ability to undergo standard radiation therapy post-operatively)Xx_NEWLINE_xXParticipants with a known breast cancer (BRCA) 1 or 2 mutationXx_NEWLINE_xXParticipants with locally advanced breast cancer such as inflammatory breast cancer or cancer grossly involving skinXx_NEWLINE_xXPatients with breast implants or expandersXx_NEWLINE_xXNew diagnosis of breast cancerXx_NEWLINE_xXNew diagnosis if a previous breast cancer patient with negative surgical marginsXx_NEWLINE_xXNewly diagnosed breast cancer patientsXx_NEWLINE_xXWomen with history of surgical, medical, or radiation therapy for breast cancerXx_NEWLINE_xXDiagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreasXx_NEWLINE_xXBreast cancer (any stage)Xx_NEWLINE_xXKnown or suspected (Breast Imaging Reporting and Data System [BIRADS] 5 on imaging) primary breast cancerXx_NEWLINE_xXAt least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast magnetic resonance imaging [MRI]); only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study; patients that have a prior diagnosis of primary breast cancer in the opposite breast can be includedXx_NEWLINE_xXHistologically confirmed estrogen receptor positive (ER+) breast cancer either from a metastatic biopsy or from a primary breast tumor with imaging evidence of metastatic disease. The pathology report and either (1) tumor tissue (blocks or unstained slides) or (2) a photomicrograph of the ER immunohistochemistry (IHC) slide from at least one site of metastatic disease and/or from primary breast cancer must be available for review and analysis.Xx_NEWLINE_xXInflammatory breast cancerXx_NEWLINE_xXPrior history of breast cancer in the ipsilateral breastXx_NEWLINE_xXPatient of Dr. Ranjna Sharma’s scheduled to undergo lumpectomy for breast cancer at Beth Israel Deaconess Medical (BIDMC)Xx_NEWLINE_xXEligible for breast conserving surgery, lumpectomy and radiationXx_NEWLINE_xXInvolvement in another therapeutic trial for breast cancer at Dana Farber or elsewhereXx_NEWLINE_xXNo prior history of breast cancerXx_NEWLINE_xXNo prior history of breast reconstruction, reduction, or augmentationXx_NEWLINE_xXKnown or suspected breast cancer with at least one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast magnetic resonance imaging [MRI]); only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study; patients that have a prior diagnosis of primary breast cancer in the opposite breast can be includedXx_NEWLINE_xXHave biopsy-proven breast cancer and decided to receive neoadjuvant chemotherapyXx_NEWLINE_xXPATIENT: Be diagnosed with breast cancerXx_NEWLINE_xXPATIENT: Patients who have had prior breast reductionXx_NEWLINE_xXPatients who will receive radiotherapy as treatment for left-sided breast cancerXx_NEWLINE_xXPatient must have histological or cytological confirmed breast cancer and fall into one of the following categories:\r\n* New diagnosis with plans for at least 6 months of neoadjuvant ET or any amount of neoadjuvant ET if surgery is planned as this will be used for response assessment \r\n* Patients with newly diagnosed metastatic breast cancer or patient with known metastatic disease who has progressed while on therapy (no washout period is needed if the patient was treated with aromatase inhibitors [AIs] or chemotherapy, but 2 months washout period is needed if the patient was treated with tamoxifen) who are going to be treated with ETXx_NEWLINE_xXHistory of progression or recurrence of disease while on an endocrine targeted therapy containing regimen as assessed by medical record review of breast cancer history at screeningXx_NEWLINE_xXHas biopsy-proven invasive breast cancer (Breast Imaging Reporting and Data System [BI-RADS] 6) and scheduled for neoadjuvant chemotherapy (NAC)Xx_NEWLINE_xXPatients with stage T1 or greater (T1-T4), nodal involvement (N0-N3), without metastasis (M0) invasive breast cancer, including patients with inflammatory breast cancerXx_NEWLINE_xXThe patient must have a histologically proven diagnosis of stage I through IIIC breast cancerXx_NEWLINE_xXBiopsy proven HER2 negative primary breast cancer and biopsy proven metastatic diseaseXx_NEWLINE_xXHigh risk: this includes patients with any of the following:\r\n* >= 20% lifetime risk of breast cancer\r\n* Breast cancer, early onset (BRCA) mutation or other hereditary germ line mutation\r\n* History of chest wall radiation\r\n* Lobular carcinoma in situ (LCIS)\r\n* History of breast cancer diagnosed at age 40 or earlier\r\n* History of breast cancer with 1st or 2nd degree relative with breast cancer and either patient or relative diagnosed at 50 years or younger\r\n* History of breast cancer with mammographically occult lesions\r\n* History of breast cancer for whom a medical oncologist feels breast MRI screening is importantXx_NEWLINE_xXScheduled for breast core needle or surgical biopsy of at least one breast lesion based on suspicious breast lesion (Breast Imaging Reporting and Data System [BIRADS] score of 4 or 5) from pre-study standard of care (SOC) imaging studiesXx_NEWLINE_xXPathologic diagnosis of invasive breast cancer or high suspicion of breast cancer based on imagingXx_NEWLINE_xXParticipants who are breast cancer free (mammogram “negative” within 1 month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with stage II or stage III breast cancer will be invited to participate in the studyXx_NEWLINE_xXFemales s/p treatment for breast cancer within last 5 yearsXx_NEWLINE_xXScheduled for mammogram, breast ultrasound and/or breast MRIXx_NEWLINE_xXNo open breast or chest woundsXx_NEWLINE_xXPatients scheduled to have a partial mastectomy or mastectomy for the treatment of breast cancerXx_NEWLINE_xXNo known or suspected breast diseaseXx_NEWLINE_xXSymptomatic of any breast abnormalityXx_NEWLINE_xXRecent breast biopsyXx_NEWLINE_xXAdult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancerXx_NEWLINE_xXBiopsy confirmed benign calcifications in at least one breast (same or contralateral breast)Xx_NEWLINE_xXPatients who have received prior treatment for the current breast cancerXx_NEWLINE_xXwith a suspicious lesion found in the breast and recommended for biopsy or have a confirmed diagnosis of cancer;Xx_NEWLINE_xXand in good health (other than having breast lesions);Xx_NEWLINE_xXPatients with a confirmed diagnosis of clinical stage 1 or 2 breast cancer who are undergoing breast cancer surgery with lumpectomy or mastectomy and planned axillary sentinel node biopsy procedure will be eligible for the studyXx_NEWLINE_xXPatients with cancer > 3 cm, clinically positive nodes, prior surgery for breast cancer in the index breast, thyroid dysfunction, hypersensitivity to iodine, and hepatic or renal insufficiency will be excluded from the studyXx_NEWLINE_xXSubjects with known or suspected breast diseaseXx_NEWLINE_xXPatients with a diagnosis of breast cancer by either core needle biopsy or excisional biopsyXx_NEWLINE_xXPatients with breast implantsXx_NEWLINE_xXSerious systemic illness other than breast cancerXx_NEWLINE_xXUnresected, untreated breast cancer that meets one of the following clinical stages:\r\n* T2, T3, or T4a-c lesion, any N, M0\r\n* Note: Patients with inflammatory breast cancer (T4d) are not eligible; bilateral cancers are permitted with approval of the Protocol Chair; participants with clinically evaluable disease will be followed for response by clinical examination; measurable disease is not required for participationXx_NEWLINE_xXReceived prior or ongoing local (e.g radiation) or systemic treatment (chemotherapy or endocrine therapy) for the current breast cancer; patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsyXx_NEWLINE_xXBREAST CANCER PARTICIPANTS: Participant has biopsy proven breast cancer and may or may not undergo surgical excision of the cancerous lesion(s)Xx_NEWLINE_xXBREAST CANCER PARTICIPANTS: Patient is able to remain still for duration of each imaging procedureXx_NEWLINE_xXBREAST CANCER PARTICIPANTS: Patients participating in other research imaging protocols will be excluded from this studyXx_NEWLINE_xXWomen with stage I-III breast cancer who began their cancer treatment 1-2 years prior to this study and have received anthracycline based chemotherapyXx_NEWLINE_xXWomen with >= 2 cm clinically or radiologically measureable breast cancerXx_NEWLINE_xXWomen who have undergone open surgical (excisional) biopsy for breast cancer diagnosisXx_NEWLINE_xXWomen who have had a prior history of breast cancer in the same breastXx_NEWLINE_xXMulticentric breast cancerXx_NEWLINE_xXPatients must have a current diagnosis of sarcoma, lymphoma, or HER2(-) breast cancerXx_NEWLINE_xXRequired studies include diagnostic mammogram of the affected breast within 3 months prior to registration, and a two-view (full view craniocaudal [CC] and a full view mediolateral oblique [MLO]) mammogram of both breasts within 6 months of registration (if the patient has only one breast, a unilateral exam of the intact breast is required)Xx_NEWLINE_xXPatients must not have known deleterious mutations in breast cancer (BRCA) genesXx_NEWLINE_xXPatients must not have received hormonal therapy (i.e., tamoxifen, raloxifene, and/or aromatase inhibitors) for prevention of breast cancer within 3 months of the biopsy documenting DCISXx_NEWLINE_xXPatient desire to undergo breast surgeryXx_NEWLINE_xXThe cancer enhances on breast MRI imagingXx_NEWLINE_xXPatient desire to undergo breast conserving surgeryXx_NEWLINE_xXMulticentric breast cancer, defined as two or more tumors in different quadrants of the breastXx_NEWLINE_xXAny history of prior radiation or chemotherapy for breast cancerXx_NEWLINE_xXHave bilateral breast cancerXx_NEWLINE_xXWill be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their oncologistXx_NEWLINE_xXHave a recurrence of ipsilateral breast cancerXx_NEWLINE_xXPatients not receiving breast surgery care from the Department of Breast Surgery at Columbia Medical CenterXx_NEWLINE_xXPatients with a prior breast cancer diagnosisXx_NEWLINE_xXPrior history of ipsilateral breast cancerXx_NEWLINE_xXNewly diagnosed with clinically node-negative breast cancer or melanoma being staged with SLN biopsyXx_NEWLINE_xXWomen at high-risk of breast cancer with an order for a clinical screening breast MRIXx_NEWLINE_xXWomen diagnosed with breast cancer within the last 6 monthsXx_NEWLINE_xXCurrent use of aromatase inhibitor as prevention or treatment for breast cancerXx_NEWLINE_xXAny patient with confirmed metastatic disease. Patients with inflammatory breast cancer.Xx_NEWLINE_xXPatients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer.Xx_NEWLINE_xXThe primary breast tumor must be detectable by mammogram or breast ultrasound at the time of diagnosisXx_NEWLINE_xXHave a prosthesis/implant in the operative breastXx_NEWLINE_xXWomen must not breast-feed while taking the study medicationsXx_NEWLINE_xXParticipants must have been clinically diagnosed with breast cancer and scheduled for axillary lymph node dissection (ALND) and radiation treatment at MD Anderson (receiving chemotherapy, mastectomy or breast-conserving surgery, ALND (>10 nodes) and radiation treatment for breast cancer, identified by Drs. Mittendorf and Shaitelman of the Nellie B. Connally Breast Cancer Center at MD Anderson)Xx_NEWLINE_xXSevere underlying chronic illness or disease (other than breast cancer)Xx_NEWLINE_xXPrior invasive breast cancer, prior mastectomy or breast radiation within 12 monthsXx_NEWLINE_xXWomen must not breast-feed while taking the study medicationsXx_NEWLINE_xXHistological or cytological confirmation of an ER+ advanced metastatic breast cancer tumour that is eligible for treatment with fulvestrantXx_NEWLINE_xXFor participants with breast cancer only:Xx_NEWLINE_xXStage I-IIIc disease:\r\n* Scheduled for lumpectomy or mastectomy\r\n* No prior or current therapy for breast cancer\r\n* Not considered candidate for therapeutic neoadjuvant treatmentXx_NEWLINE_xXProviding surgical treatment for newly diagnosed breast cancer patientsXx_NEWLINE_xXPHASE II: Women newly diagnosed with breast cancer on the day they meet with their surgeon for their initial consultation after the visitXx_NEWLINE_xXPHASE I: Women diagnosed with Paget’s disease, inflammatory breast cancer or a phyllodes tumorXx_NEWLINE_xXPHASE I: Women who state that there are still deciding on breast cancer treatment (e.g., whether or not to take hormone therapy or to receive radiation treatment)Xx_NEWLINE_xXPHASE II: women who state that there are still deciding on breast cancer treatmentXx_NEWLINE_xXWithin 6 weeks of a new line of breast cancer therapy and/or progression on scans and/or a change in current breast cancer therapy regimenXx_NEWLINE_xXPatient: Had a mastectomy for breast cancer no more than 5 years prior to enrollmentXx_NEWLINE_xXSurgeon: Performs breast reconstruction procedures after mastectomyXx_NEWLINE_xXNurse: Involved in the perioperative care of patients with breast cancerXx_NEWLINE_xXNewly diagnosed breast cancerXx_NEWLINE_xXWomen who (1) have a personal history of a single stage 0-2 breast cancer, (2) were recently diagnosed within the past 6 months, and (3) are treated at a participating breast oncology clinic.Xx_NEWLINE_xXBreast implants allowedXx_NEWLINE_xXStage 4 breast cancerXx_NEWLINE_xXDiagnosed with hormone receptor-positive breast cancer and prescribed endocrine hormonal treatment (EHT)Xx_NEWLINE_xXNewly diagnosed female breast cancer patients scheduled to see one of four breast surgeons at the Huntsman Cancer Hospital Breast Surgery Clinic at the University of UtahXx_NEWLINE_xXPatients who have had breast cancer previouslyXx_NEWLINE_xXLatinas diagnosed with breast cancerXx_NEWLINE_xXAttend the Cancer Therapy and Research Center (CTRC) breast clinicXx_NEWLINE_xXTreat patients diagnosed with breast, prostate or colorectal cancerXx_NEWLINE_xXPatient’s breast cancer has not recurred during the time periodXx_NEWLINE_xXNo prior treatment with chemotherapy for a diagnosis of locoregionally recurrent or metastatic breast cancer is allowed.Xx_NEWLINE_xXPregnant at the time of diagnosis of their breast cancer.Xx_NEWLINE_xXPrior ipsilateral breast cancer surgeries, mastectomies, breast reconstructions or implants.Xx_NEWLINE_xXPrior ipsilateral reduction mammoplasties (breast reductions) performed less than 2 years prior to enrollment to this study.Xx_NEWLINE_xXCriteria1, Participant provided informed consent prior to any study-specific activities/procedures -Criteria 2, Confirmation of triple negative breast cancer or colorectal cancer with liver metastases by laboratory testingXx_NEWLINE_xXBreast cancer non-candidate for hormone therapy alone.Xx_NEWLINE_xXDiagnosis of primary breast cancer.Xx_NEWLINE_xXpositive clinical breast examinationXx_NEWLINE_xXDiffuse tumors or multiple malignant tumors in the breast.Xx_NEWLINE_xXPrior breast malignancy of the ipsilateral breast.Xx_NEWLINE_xXRequiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors.Xx_NEWLINE_xXInclusion Criteria:\n\n        All subjects:\n\n          -  Pathologically confirmed diagnosis of solid tumors\n\n          -  Metastatic disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1\n\n          -  Adequate bone marrow, hepatic and renal function\n\n          -  Normal Electrocardiogram (ECG)\n\n          -  18 years of age or above\n\n          -  Able to understand and sign informed consent\n\n        Pilot study only:\n\n        - CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer,\n        Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer\n\n        Expansion Phase Additional Criteria:\n\n          -  Locally advanced or metastatic breast cancer\n\n          -  Received at least one cytotoxic therapy in the locally advanced and metastatic setting\n\n          -  Received ? 5 prior lines of chemotherapy in the metastatic setting\n\n          -  Candidate for chemotherapy\n\n        Expansion Phase Cohort 3 additional inclusion criteria:\n\n          -  Breast cancer with active brain metastasis\n\n          -  Neurologically stable\n\n        Exclusion Criteria:\n\n          -  Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion\n             phase cohort 1 and 2 only)\n\n          -  Clinically significant GI disorders\n\n          -  Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase\n             patients, have received any prior treatment with Topol inhibitor\n\n          -  Known hypersensitivity to MM-398 or ferumoxytol\n\n          -  Inability to undergo MRI\n\n          -  Active infection\n\n          -  Pregnant or breast feeding\n\n          -  Prior chemotherapy administered within 3 weeks, or within a time interval less than at\n             least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day\n             of dosing in this study\n\n          -  Received radiation therapy in the last 14 days\n\n          -  Treated with parenteral iron in the previous 4 weeksXx_NEWLINE_xXSubjects with prior breast surgeries, mastectomies, breast reconstructions or implants. (Note: subjects who have had prior breast biopsies are not excluded)Xx_NEWLINE_xXSubjects with prior reduction mammoplasties or breast reductions performed less than 2 years prior to enrollment to this study.Xx_NEWLINE_xXHas locally recurrent inoperable breast cancer not previously treated with chemotherapy and which cannot be treated with curative intent OR has metastatic breast cancer not previously treated with chemotherapy.Xx_NEWLINE_xXHas completed treatment for Stage I-III breast cancer, if indicated, and ?6 months elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence.Xx_NEWLINE_xXPrior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.Xx_NEWLINE_xXExperienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.Xx_NEWLINE_xXAdult women with breast cancer who have undergone surgery for their primary breast tumor (either lumpectomy or mastectomy +/- reconstruction) and are confirmed to have involved lymph nodes on surgical pathologyXx_NEWLINE_xXWomen with T4 disease, including inflammatory breast cancerXx_NEWLINE_xXPatients with synchronous bilateral breast cancersXx_NEWLINE_xXHistopathologically confirmed metastatic breast cancerXx_NEWLINE_xXAt least 2 prior HER2-directed therapy regimens for metastatic breast cancer, including trastuzumab and TDM-1.Xx_NEWLINE_xX